L-CARNITINE

OTHER NAME(S):

3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium inner salt, (3-carboxy2-hydroxypropyl) trimethylammonium hydroxide inner salt, 3-hydroxy-4-N-trimethylaminobutyrate, B-hydroxy-N-trimethyl aminobutyric acid, Beta-hydroxy-gamma-trimethylammonium butyrate, B(t) Factor, Carnitine, Carnitor, D-Carnitine, DL-Carnitine, Facteur B(t), L-3-hydroxy-4-(trimethylammonium)-butyrate, Levocarnitine, Lévocarnitine, Levocarnitine Fumurate, L-Carnitina, L-Carnitine Fumarate, L-Carnitine L-Tartrate, L-Carnitine Tartrate, (R)-(3-carboxy-2-hydroxypropyl) trimethylammonium hydroxide, (R)-3-hydroxy-4-trimethylammonio-butyrate, Vitacarn, Vitamin B(t), Vitamine B(t).<br/><br/>

Overview

Overview Information

L-carnitine is an amino acid (a building block for proteins) that is naturally produced in the body.

L-carnitine supplements are used to increase L-carnitine levels in people whose natural level of L-carnitine is too low because they have a genetic disorder, are taking certain drugs (valproic acid for seizures), or because they are undergoing a medical procedure (hemodialysis for kidney disease) that uses up the body's L-carnitine. It is also used as a replacement supplement in strict vegetarians, dieters, and low-weight or premature infants.

L-carnitine is used for conditions of the heart and blood vessels including heart-related chest pain, congestive heart failure (CHF), heart complications of a disease called diphtheria, heart attack, leg pain caused by circulation problems (intermittent claudication), and high cholesterol.

Some people use L-carnitine for muscle disorders associated with certain AIDS medications, difficulty fathering a child (male infertility), a brain development disorder called Rett syndrome, anorexia, chronic fatigue syndrome, diabetes, overactive thyroid, attention deficit-hyperactivity disorder (ADHD), leg ulcers, Lyme disease, and to improve athletic performance and endurance.

The body can convert L-carnitine to other amino acids called acetyl-L-carnitine and propionyl-L-carnitine. But, no one knows whether the benefits of carnitines are interchangeable. Until more is known, don't substitute one form of carnitine for another.

How does it work?

L-carnitine helps the body produce energy. It is important for heart and brain function, muscle movement, and many other body processes.

Uses

Uses & Effectiveness?

Effective for

  • Serious kidney disease. Most research suggests that taking L-carnitine by mouth or intravenously (by IV) can improve red blood cell counts during hemodialysis. The US Food and Drug Administration (FDA) has approved L-carnitine for the treatment and prevention of L-carnitine deficiency in people with serious kidney disease who are undergoing hemodialysis.
  • L-carnitine deficiency. The FDA has approved L-carnitine for treating L-carnitine deficiency caused by certain genetic diseases.

Possibly Effective for

  • Chest pain (angina). Taking L-carnitine by mouth seems to improve exercise tolerance in people with chest pain. Taking L-carnitine along with standard treatment also seems to reduce chest pain and improve exercise ability in people who have chest pain but not blocked arteries.
  • Heart failure. Taking L-carnitine by mouth seems to improve symptoms and increase exercise ability in people with heart failure. Taking a specific product containing L-carnitine and coenzyme Q-10 (Carni Q-Gel) also appears to improve symptoms of heart failure.
  • High thyroid hormone levels (hyperthyroidism). Taking L-carnitine seems to improve symptoms such as rapid or pounding heartbeat, nervousness, and weakness in people with high thyroid hormone levels.
  • Male infertility. Most research shows that taking L-carnitine, alone or in combination with acetyl-L-carnitine, increases sperm count and sperm movement in men with fertility problems.
  • Inflammation of the heart (myocarditis). Taking L-carnitine by mouth seems to reduce the risk of death from myocarditis.
  • Preventing side effects caused by valproic acid (Depacon, Depakene, Depakote, VPA), a seizure medication. Using L-carnitine intravenously (by IV) can prevent the side effects of valproic acid.

Insufficient Evidence for

  • Age-related fatigue. Taking L-carnitine might improve physical and mental fatigue, increase muscle mass, and decrease fat mass in elderly people.
  • Hair loss (androgenic alopecia). Early research suggests that applying an L-carnitine solution twice daily for 6 months increases hair on the scalp.
  • Athletic performance. Intense exercise has been linked to a decrease in L-carnitine blood levels. However, research on the use of L-carnitine for improving athletic performance is inconsistent. Some studies suggest that L-carnitine improves athletic performance and endurance. However, other research suggests L-carnitine provides no benefits.
  • Attention deficit-hyperactivity disorder (ADHD). Taking L-carnitine does not appear to reduce ADHD symptoms in most children.
  • Autism. Early research suggests that taking L-carnitine by mouth daily for 3 months reduces the severity of autism in children according to some but not all scales.
  • Irregular heartbeat (arrhythmia). Early research suggests that L-carnitine might reduce irregular heartbeat.
  • Blood disorder called beta-thalassemia. Early research suggests that L-carnitine might reduce symptoms of a blood disorder called beta-thalassemia.
  • Wasting syndrome (cachexia). Early research suggests that taking L-carnitine can increase body mass index (BMI) and improve lean body mass in people with cancer and wasting syndrome.
  • Weakening heart muscle (cardiomyopathy). Early research suggests that L-carnitine improves heart function in adults or children with a weak heart muscle.
  • Cancer-related fatigue. Some cancer patients have low blood levels of L-carnitine. Some early research suggests that taking L-carnitine might improve fatigue in advanced cancer patients. However, other research suggests that it has no benefit.
  • Celiac disease-related fatigue. Some research shows that taking L-carnitine seems to help fatigue associated with celiac disease. However, L-carnitine does not seem to improve depression or quality of life.
  • Chronic fatigue syndrome. Early research suggests that taking L-carnitine for 2 months can improve symptoms of fatigue.
  • Lung disease (chronic obstructive pulmonary disease). Early research suggests that L-carnitine can improve exercise performance in people with chronic obstructive pulmonary disease (COPD).
  • Clogged arteries (coronary artery disease). Early research suggests that taking L-carnitine before exercise does not improve endurance in people with clogged arteries.
  • Diabetes. Some research suggests that L-carnitine might improve blood sugar control, but most research shows that L-carnitine does not improve blood sugar in people with diabetes. However, L-carnitine might improve glycemic control when taken along with certain diabetes medications.
  • Fatigue. Early research shows that taking L-carnitine daily for 8 days does not reduce fatigue in healthy people.
  • Fragile-X syndrome. Some research suggests that L-carnitine reduces hyperactive behavior in children with fragile-X syndrome.
  • Declining brain function related to liver disease. Early research shows that taking L-carnitine daily for 60-90 days reduces ammonia levels and improves brain function in people with declining brain function related to severe liver disease.
  • Fatigue due to hepatitis. Early research shows that taking L-carnitine daily reduces fatigue in people with hepatitis C who are also being treated with medication.
  • Hepatitis C. Taking L-carnitine with the medications interferon-alpha and ribavirin seems to improve the response to treatment in people with hepatitis C.
  • High lipid (fat) levels in the blood. Early research shows that taking L-carnitine daily can reduce total cholesterol, low-density lipoprotein (LDL or "bad") cholesterol, and triglycerides in children with high lipid levels. Also, taking L-carnitine can reduce levels of lipoprotein(a), a possible risk factor for cardiovascular disease, in people with high levels of lipoprotein(a).
  • High triglycerides. Early research suggests that L-carnitine does not reduce triglyceride levels in people with high triglyceride levels.
  • Low birth weight. Some research suggests that giving premature infants L-carnitine by mouth or intravenously (by IV) can increase weight. However, other research suggests that it does not increase body weight in premature infants.
  • Memory. Early research shows that taking L-carnitine daily for 3 days does not improve memory in young adult females.
  • Migraine headache. Early research suggests that taking L-carnitine daily, with or without magnesium oxide for 12 weeks, does not reduce migraines.
  • Multiple sclerosis-related fatigue. Some people with multiple sclerosis have low blood levels of L-carnitine. Early research shows that taking L-carnitine daily decreases some aspects of fatigue in people with multiple sclerosis who also have low L-carnitine levels.
  • Heart attack. There is inconsistent evidence about the effects of using of L-carnitine after a heart attack. Some research suggests that taking L-carnitine by mouth after a heart attack improves heart function and reduces the risk of death. However, other studies suggest that it provides no benefit.
  • Breathing problems while sleeping in infants. Early research suggests that adding L-carnitine to intravenous (IV) nutrition does not reduce breathing problems while sleeping in infants.
  • Nonalcoholic liver disease (nonalcoholic steatohepatitis, NASH). Early research suggests that L-carnitine improves some aspects of liver function in people with liver disease not related to drinking alcohol.
  • Blocked blood vessels not in the heart or brain. Some early research suggests that L-carnitine might improve walking in people with blocked blood vessels not in the heart or brain. However, other research suggests that it does not provide any benefits.
  • A rare inherited disorder that affects the nervous system (Rett syndrome). Taking L-carnitine might improve well-being and movement in girls with Rett syndrome.
  • Weight loss. Taking L-carnitine by itself does not appear to reduce body weight in overweight or obese people. However, other research suggests that taking L-carnitine with certain other medications or supplements appears to reduce body weight and body mass index.
  • Eating disorders.
  • Leg ulcers.
  • Lyme disease.
  • Other conditions.
More evidence is needed to rate L-carnitine for these uses.

Side Effects

Side Effects & Safety

L-carnitine is LIKELY SAFE for most people when taken by mouth and when used as an injection, with the approval of a healthcare provider. It can cause side effects such as nausea, vomiting, stomach upset, heartburn, diarrhea, and seizures. It can also cause the urine, breath, and sweat to have a "fishy" odor.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There is not enough reliable information about the safety of using L-carnitine if you are pregnant. Stay on the safe side and avoid use.

Taking L-carnitine is POSSIBLY SAFEin breast-feeding women when taken by mouth in the amounts recommended. Small amounts of L-carnitine have been given to infants in breast milk and formula with no reported side effects. The effects of large amounts taken by a breast-feeding mother are unknown.

Children: L-carnitine is POSSIBLY SAFE when used appropriately by mouth or intravenously (by IV), short-term.

Under-active thyroid (hypothyroidism): Taking L-carnitine might make symptoms of hypothyroidism worse.

Kidney failure: Using DL-carnitine has been reported to cause symptoms such as muscle weakness and eye drooping when administered intravenously (by IV) after dialysis. L-carnitine does not seem have this effect.

Seizures: L-carnitine seems to make seizures more likely in people who have had seizures before. If you have had a seizure, do not use L-carnitine.

Interactions

Interactions?

Moderate Interaction

Be cautious with this combination

!
  • Acenocoumarol (Sintrom) interacts with L-CARNITINE

    Acenocoumarol (Sintrom) is used to slow blood clotting. L-carnitine might increase the effectiveness of acenocoumarol (Sintrom). Increasing the effectiveness of acenocoumarol (Sintrom) might slow blood clotting too much. The dose of your acenocoumarol (Sintrom) might need to be changed.

  • Thyroid hormone interacts with L-CARNITINE

    L-carnitine seems to decrease how well thyroid hormone works in the body. Taking L-carnitine with thyroid hormone might decrease the effectiveness of the thyroid hormone.

  • Warfarin (Coumadin) interacts with L-CARNITINE

    Warfarin (Coumadin) is used to slow blood clotting. L-carnitine might increase the effects of warfarin (Coumadin) and increase the chances of bruising and bleeding. Be sure to have your blood checked regularly. The dose of your warfarin (Coumadin) might need to be changed.

Dosing

Dosing

The following doses have been studied in scientific research:

BY MOUTH:

  • For L-carnitine deficiencies in adults: 990 mg two to three times per day in tablets or as an oral solution.
  • For preventing side effects caused by valproic acid (Depacon, Depakene, Depakote, VPA): 50 to 100 mg/kg/day in three or four divided doses, to a maximum of 3 grams/day.
  • For chest pain and congestive heart failure (CHF): 1 gram twice daily.
  • Following heart attack: 2 to 6 grams daily.
  • For symptoms of overactive thyroid: 1-2 grams twice daily.
  • For male infertility: 2 grams of L-carnitine plus 1 gram of L-acetyl-carnitine daily.

View References

REFERENCES:

  • Abbasi, S. H., Heidari, S., Mohammadi, M. R., Tabrizi, M., Ghaleiha, A., and Akhondzadeh, S. Acetyl-L-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry Hum.Dev. 2011;42(3):367-375. View abstract.
  • Abbott CA, Vileikyte L, Williamson S, and et al. Effect of treatment with acetyl-l-carnitine on diabetic foot ulceration in patients with peripheral neuropathy: a 1 year prospective multi-centre study. Diabetologia 1997;40:A556.
  • Abd-Allah, A. R., Helal, G. K., Al-Yahya, A. A., Aleisa, A. M., Al-Rejaie, S. S., and Al-Bakheet, S. A. Pro-inflammatory and oxidative stress pathways which compromise sperm motility and survival may be altered by L-carnitine. Oxid.Med.Cell Longev. 2009;2(2):73-81. View abstract.
  • Abdel-Azid MT, Abdou MS, Soliman K, and et al. Effect of carnitine on blood lipid pattern in diabetic patients. Nutr Rep Internat 1984;29:1071-1079.
  • Ahmet, U., Abdurrahman, K., Sait, B., Ahmet, E., Salih, D., Mendane, S., Ates, Y., Fatih, B., Necmettin, K., and Kemal, D. L-carnitine therapy in non-alcoholic steatohepatitis. Turk.J Pediatr. 2000;11(3):196-201.
  • Al'miasheva, M. I., Balashov, V. P., Ivianskii, S. A., Markelova, I. A., Kul'kova, N. P., and Balykova, L. A. [Experimental study of the effects of metabolic drugs on exercise tolerance]. Vopr.Kurortol.Fizioter.Lech.Fiz Kult. 2007;(4):15-17. View abstract.
  • Al-Sannaa, N. A. and Cheriyan, G. M. Carnitine-acylcarnitine translocase deficiency. Clinical course of three Saudi children with a severe phenotype. Saudi.Med.J 2010;31(8):931-934. View abstract.
  • Aledo, R., Mir, C., Dalton, R. N., Turner, C., Pie, J., Hegardt, F. G., Casals, N., and Champion, M. P. Refining the diagnosis of mitochondrial HMG-CoA synthase deficiency. J Inherit.Metab Dis 2006;29(1):207-211. View abstract.
  • Allegra, C., Antignani, P. L., Schachter, I., Koverech, A., Messano, M., and Virmani, A. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease. Ann.Vasc.Surg. 2008;22(4):552-558. View abstract.
  • Altmann P, Thompson C Graham K Ringrose T Taylor D Styles P Radda G. Randomized placebo controlled study on intravenous L-carnitine supplementation in hemodialysis patients-No benefit in vivo magnetic resonance spectroscopic assessment of muscle [abstract]. 1999;
  • Altunbasak, S., Baytok, V., Tasouji, M., Herguner, O., Burgut, R., and Kayrin, L. Asymptomatic hyperammonemia in children treated with valproic acid. J Child Neurol. 1997;12(7):461-463. View abstract.
  • Alvarez, T. M., Guardiola, P. D., Roldan, J. O., Elviro, R., Wevers, R., and Guijarro, G. [Primary trimethylaminuria: the fish odor syndrome]. Endocrinol.Nutr. 2009;56(6):337-340. View abstract.
  • Amadeo A, Bonollo L, Botto G, and et al. [Evaluation of efficacy of propionyl-L-carnitine in chronic oral administration on cardiac muscle efficiency, on tolerance to exercise and on life quality of patients with chronic cardiac failure. Double blind comparison with L-carnitine and placebo]. Rass Int Clin Ter 1992;72(3):117-131.
  • Amen, D. G., Wu, J. C., Taylor, D., and Willeumier, K. Reversing brain damage in former NFL players: implications for traumatic brain injury and substance abuse rehabilitation. J Psychoactive Drugs 2011;43(1):1-5. View abstract.
  • Amin, K. A. and Nagy, M. A. Effect of Carnitine and herbal mixture extract on obesity induced by high fat diet in rats. Diabetol.Metab Syndr. 2009;1(1):17. View abstract.
  • Andreozzi, G. M., Leone, A., Laudani, R., Martin, R., Deinit, G., and Cataldi, V. Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology 2008;59(1):84-89. View abstract.
  • Angelini, C., Federico, A., Reichmann, H., Lombes, A., Chinnery, P., and Turnbull, D. Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur.J Neurol. 2006;13(9):923-929. View abstract.
  • Annadurai, T., Vigneshwari, S., Thirukumaran, R., Thomas, P. A., and Geraldine, P. Acetyl-L-carnitine prevents carbon tetrachloride-induced oxidative stress in various tissues of Wistar rats. J Physiol Biochem. 2011;67(4):519-530. View abstract.
  • Anonymous. Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J 1999;20(1):70-76. View abstract.
  • Arbeiter, A. K., Kranz, B., Wingen, A. M., Bonzel, K. E., Dohna-Schwake, C., Hanssler, L., Neudorf, U., Hoyer, P. F., and Buscher, R. Continuous venovenous haemodialysis (CVVHD) and continuous peritoneal dialysis (CPD) in the acute management of 21 children with inborn errors of metabolism. Nephrol.Dial Transplant 2010;25(4):1257-1265. View abstract.
  • Ardissone P, Baccolla D, Barberis L, and et al. The effects of treatment with L-carnitine of hypoglycemia in preterm AGA infants. Curr Ther Res 1985;38:256-264.
  • Arduini, A., Bonomini, M., Clutterbuck, E. J., Laffan, M. A., and Pusey, C. D. Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients. Nephrol.Dial Transplant 2006;21(9):2671-2672. View abstract.
  • Arenas, J., Ricoy, J. R., Encinas, A. R., Pola, P., D'Iddio, S., Zeviani, M., Didonato, S., and Corsi, M. Carnitine in muscle, serum, and urine of nonprofessional athletes: effects of physical exercise, training, and L-carnitine administration. Muscle Nerve 1991;14(7):598-604. View abstract.
  • Arnold, L. E., Amato, A., Bozzolo, H., Hollway, J., Cook, A., Ramadan, Y., Crowl, L., Zhang, D., Thompson, S., Testa, G., Kliewer, V., Wigal, T., McBurnett, K., and Manos, M. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J Child Adolesc.Psychopharmacol. 2007;17(6):791-802. View abstract.
  • Arockia Rani, P. J. and Panneerselvam, C. Carnitine as a free radical scavenger in aging. Exp Gerontol. 2001;36(10):1713-1726. View abstract.
  • Arrigo, A., Casale, R., Buonocore, M., and Ciano, C. Effects of acetyl-L-carnitine on reaction times in patients with cerebrovascular insufficiency. Int J Clin Pharmacol Res 1990;10(1-2):133-137. View abstract.
  • Asilsoy, S., Bekem, O., Karaman, O., Uzuner, N., and Kavukcu, S. Serum total and free carnitine levels in children with asthma. World J Pediatr. 2009;5(1):60-62. View abstract.
  • Augustyniak, A., Stankiewicz, A., and Skrzydlewska, E. The Influence of L-Carnitine on Oxidative Modification of LDL In Vitro. Toxicol.Mech.Methods 2008;18(6):455-462. View abstract.
  • Auinger, K., Muller, V., Rudiger, A., and Maggiorini, M. Valproic acid intoxication imitating brain death. Am.J Emerg.Med. 2009;27(9):1177-6. View abstract.
  • Azevedo, O., Vilarinho, L., Almeida, F., Ferreira, F., Guardado, J., Ferreira, M., Lourenco, A., Medeiros, R., and Almeida, J. Cardiomyopathy and kidney disease in a patient with maternally inherited diabetes and deafness caused by the 3243A>G mutation of mitochondrial DNA. Cardiology 2010;115(1):71-74. View abstract.
  • Azumano, I. and Yamanishi, T. A new use of pantothenic acid in metabolic syndrome treatment. Kagaku to Seibutsu 2008;46(6):400-404.
  • Bain, M. A., Faull, R., Milne, R. W., and Evans, A. M. Oral L-carnitine: metabolite formation and hemodialysis. Curr.Drug Metab 2006;7(7):811-816. View abstract.
  • Bajerska, J., Jeszka, J., Czapka-Matyasik, M., and Kostrzewa-Tarnowska, A. [Does L-carnitine supplementation can improve physical performance of athletes?]. Zywienie Czowieka i Metabolizm 2009;36(1):118-123.
  • Baker, S. K. and Lipson, D. M. Vincristine-induced peripheral neuropathy in a neonate with congenital acute lymphoblastic leukemia. J Pediatr.Hematol.Oncol. 2010;32(3):e114-e117. View abstract.
  • Balasaraswathi, K., Rajasekar, P., and Anuradha, C. V. Changes in redox ratio and protein glycation in precataractous lens from fructose-fed rats: effects of exogenous L-carnitine. Clin Exp.Pharmacol Physiol 2008;35(2):168-173. View abstract.
  • Balercia, G., Regoli, F., Armeni, T., Koverech, A., Mantero, F., and Boscaro, M. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil.Steril. 2005;84(3):662-671. View abstract.
  • Balogh, D., Hackl, J. M., Legenstein, E., and Musil, H. E. [Experiences with L-carnitine in the post-stress phase]. Infusionsther.Klin Ernahr. 1986;13(5):204-208. View abstract.
  • Bangma, H. R., Smit, G. P., Kuks, J. B., Grevink, R. G., and Wolffenbuttel, B. H. [Two patients with mitochondrial respiratory chain disease]. Ned.Tijdschr.Geneeskd. 10-18-2008;152(42):2298-2301. View abstract.
  • Barker, G. A., Green, S., Askew, C. D., Green, A. A., and Walker, P. J. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Med Sci Sports Exerc. 2001;33(9):1415-1422. View abstract.
  • Bassi S, Ferrarese C, Finoia MG, and et al. L-acetyl-carnitine in Alzheimer disease (A.D.) and senile dementia Alzheimer type (S.D.A.T.). Senile Dementias.II International Symposium 1988;461-466.
  • Battistin L, Pizzolato G, Dam M, and et al. Effects of acetyl-L-carnitine (ALC) treatment in dementia: A multicentric, randomized, double-blind study. New Trends Clin Neuropharmacol 1989;3(2):131-132.
  • Baudouin, C., Cochener, B., Pisella, P. J., Girard, B., Pouliquen, P., Cooper, H., and Creuzot-Garcher, C. Randomized, phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease. Eur.J Ophthalmol. 2012;22(5):751-761. View abstract.
  • Bavbek, N., Akay, H., Uz, B., Uz, E., Turgut, F., Kanbay, M., Senes, M., Akcay, A., and Duranay, M. The effects of L-carnitine therapy on respiratory function tests in chronic hemodialysis patients. Ren Fail. 2010;32(2):157-161. View abstract.
  • Bazzato, G., Mezzina, C., Ciman, M., and Guarnieri, G. Myasthenia-like syndrome associated with carnitine in patients on long- term haemodialysis. Lancet 5-12-1979;1(8124):1041-1042. View abstract.
  • Bellinghieri, G., Savica, V., Barbera, C. M., Ricciardi, B., Egitto, M., Torre, F., Valentini, G., D'Iddio, S., Bagiella, E., Mallamace, A., and . L-carnitine and platelet aggregation in uremic patients subjected to hemodialysis. Nephron 1990;55(1):28-32. View abstract.
  • Bellinghieri, G., Savica, V., Mallamace, A., Di, Stefano C., Consolo, F., Spagnoli, L. G., Villaschi, S., Palmieri, G., Corsi, M., and Maccari, F. Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am.J Clin Nutr. 1983;38(4):523-531. View abstract.
  • Benedini, S., Perseghin, G., Terruzzi, I., Scifo, P., Invernizzi, P. L., Del, Maschio A., Lazzarin, A., and Luzi, L. Effect of L-acetylcarnitine on body composition in HIV-related lipodystrophy. Horm.Metab Res. 2009;41(11):840-845. View abstract.
  • Benton, D. and Donohoe, R. T. The influence on cognition of the interactions between lecithin, carnitine and carbohydrate. Psychopharmacology (Berl) 2004;175(1):84-91. View abstract.
  • Bernard, A., Rigault, C., Mazue, F., Le, Borgne F., and Demarquoy, J. L-carnitine supplementation and physical exercise restore age-associated decline in some mitochondrial functions in the rat. J Gerontol.A Biol.Sci Med.Sci 2008;63(10):1027-1033. View abstract.
  • Bertoli, M., Battistella, P. A., Vergani, L., Naso, A., Gasparotto, M. L., Romagnoli, G. F., and Angelini, C. Carnitine deficiency induced during hemodialysis and hyperlipidemia: effect of replacement therapy. Am J Clin Nutr 1981;34(8):1496-1500. View abstract.
  • Biagini, A., Opie, L., Rovai, D., Mazzei, M. G., Carpeggiani, C., and Maseri, A. Intravenous dl-carnitine fails to increase the double-product during atrial pacing in patients with effort angina. A double-blind randomized study. G Ital Cardiol 1983;13(11):291-294. View abstract.
  • Bianchi, G., Vitali, G., Caraceni, A., Ravaglia, S., Capri, G., Cundari, S., Zanna, C., and Gianni, L. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine. Eur.J Cancer 7-19-2005; View abstract.
  • Bijarnia, S., Wiley, V., Carpenter, K., Christodoulou, J., Ellaway, C. J., and Wilcken, B. Glutaric aciduria type I: outcome following detection by newborn screening. J Inherit.Metab Dis 2008;31(4):503-507. View abstract.
  • Biolo, G., Stulle, M., Bianco, F., Mengozzi, G., Barazzoni, R., Vasile, A., Panzetta, G., and Guarnieri, G. Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Nephrol.Dial Transplant 2008;23(3):991-997. View abstract.
  • Bjornsson, E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol.Scand. 2008;118(5):281-290. View abstract.
  • Block, K. I., Koch, A. C., Mead, M. N., Tothy, P. K., Newman, R. A., and Gyllenhaal, C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int.J Cancer 9-15-2008;123(6):1227-1239. View abstract.
  • Bloomer, R. J., Farney, T. M., Trepanowski, J. F., McCarthy, C. G., Canale, R. E., and Schilling, B. K. Comparison of pre-workout nitric oxide stimulating dietary supplements on skeletal muscle oxygen saturation, blood nitrate/nitrite, lipid peroxidation, and upper body exercise performance in resistance trained men. J Int.Soc.Sports Nutr. 2010;7:16. View abstract.
  • Bloomer, R. J., Tschume, L. C., and Smith, W. A. Glycine propionyl-L-carnitine modulates lipid peroxidation and nitric oxide in human subjects. Int.J Vitam.Nutr.Res. 2009;79(3):131-141. View abstract.
  • Bohles H, Noppeney T, Akcetin Z, and et al. The effect of preoperative L-carnitine supplementation on myocardial metabolism during aorto-coronary-bypass surgery. Current Therapeutic Research 1986;39(3):429-435.
  • Bohmer, T., Boen, A., and Hoymork, S. C. Valproate-induced hyperammonemic encephalopathy, rapidly improved by i.v. carnitine and glucose/thiamine. Scand.J Gastroenterol. 2010;45(6):762-763. View abstract.
  • Bolognesi, M., Amodio, P., Merkel, C., Godi, L., and Gatta, A. Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease. Clin Physiol 1995;15(5):417-423. View abstract.
  • Bonavita E, Bertuzzi D, Bonavita J, and et al. L-acetylcarnitine (L-AC) (Branigen) in the long term symptomatic treatment of senile dementia. Clin Trials J 1988;25:227-237.
  • Bonavita, E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol.Ther Toxicol. 1986;24(9):511-516. View abstract.
  • Boneh, A., Beauchamp, M., Humphrey, M., Watkins, J., Peters, H., and Yaplito-Lee, J. Newborn screening for glutaric aciduria type I in Victoria: treatment and outcome. Mol.Genet.Metab 2008;94(3):287-291. View abstract.
  • Bonilla, Guerrero R., Wolfe, L. A., Payne, N., Tortorelli, S., Matern, D., Rinaldo, P., Gavrilov, D., Melan, M., He, M., Steinberg, S. J., Raymond, G. V., Vockley, J., and Gibson, K. M. Essential fatty acid profiling for routine nutritional assessment unmasks adrenoleukodystrophy in an infant with isovaleric acidaemia. J Inherit.Metab Dis 2008;31 Suppl 2:S453-S456. View abstract.
  • Borghi-Silva, A., Baldissera, V., Sampaio, L. M., Pires-DiLorenzo, V. A., Jamami, M., Demonte, A., Marchini, J. S., and Costa, D. L-carnitine as an ergogenic aid for patients with chronic obstructive pulmonary disease submitted to whole-body and respiratory muscle training programs. Braz.J Med.Biol.Res. 2006;39(4):465-474. View abstract.
  • Brass, E. P., Adler, S., Sietsema, K. E., Hiatt, W. R., Orlando, A. M., and Amato, A. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis. 2001;37(5):1018-1028. View abstract.
  • Brass, E. P., Hoppel, C. L., and Hiatt, W. R. Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans. Clin Pharmacol Ther 1994;55(6):681-692. View abstract.
  • Brevetti G, Chiariello M, Policicchio A, and et al. L-carnitine increases walking distance in patients with peripheral artery disease. Eur Heart J 1984;5(Abstr Suppl 1):138.
  • Brevetti, G., Attisano, T., Perna, S., Rossini, A., Policicchio, A., and Corsi, M. Effect of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, crossover study. Angiology 1989;40(10):857-862. View abstract.
  • Brevetti, G., di Lisa, F., Perna, S., Menabo, R., Barbato, R., Martone, V. D., and Siliprandi, N. Carnitine-related alterations in patients with intermittent claudication: indication for a focused carnitine therapy. Circulation 5-1-1996;93(9):1685-1689. View abstract.
  • Broad, E. M., Maughan, R. J., and Galloway S DR. Effects of exercise intensity and altered substrate availability on cardiovascular and metabolic responses to exercise after oral carnitine supplementation in athletes. Int.J Sport Nutr.Exerc.Metab 2011;21(5):385-397. View abstract.
  • Brunel-Guitton, C., Costa, T., Mitchell, G. A., and Lambert, M. Treatment of cobalamin C (cblC) deficiency during pregnancy. J Inherit.Metab Dis 9-10-2010; View abstract.
  • Cai, H., Yi, W., Li, M., and et al. The effect of levocarnitine for plasmatic matrix metalloproteinases (MMPS) on acute cerebral infarct patients. Modern Preventive Med. 2010;37(12):2353-2354.
  • Cai, T., Wagenlehner, F. M., Mazzoli, S., Meacci, F., Mondaini, N., Nesi, G., Tiscione, D., Malossini, G., and Bartoletti, R. Semen quality in patients with Chlamydia trachomatis genital infection treated concurrently with prulifloxacin and a phytotherapeutic agent. J Androl 2012;33(4):615-623. View abstract.
  • Calabrese, V., Colombrita, C., Sultana, R., Scapagnini, G., Calvani, M., Butterfield, D. A., and Stella, A. M. Redox modulation of heat shock protein expression by acetylcarnitine in aging brain: relationship to antioxidant status and mitochondrial function. Antioxid.Redox.Signal. 2006;8(3-4):404-416. View abstract.
  • Calabrese, V., Cornelius, C., Mancuso, C., Lentile, R., Stella, A. M., and Butterfield, D. A. Redox homeostasis and cellular stress response in aging and neurodegeneration. Methods Mol.Biol. 2010;610:285-308. View abstract.
  • Calabrese, V., Cornelius, C., Stella, A. M., and Calabrese, E. J. Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes. Neurochem.Res. 2010;35(12):1880-1915. View abstract.
  • Calabrese, V., Giuffrida Stella, A. M., Calvani, M., and Butterfield, D. A. Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J Nutr.Biochem. 2006;17(2):73-88. View abstract.
  • Calandrella, N., De, Seta C., Scarsella, G., and Risuleo, G. Carnitine reduces the lipoperoxidative damage of the membrane and apoptosis after induction of cell stress in experimental glaucoma. Cell Death.Dis 2010;1:e62. View abstract.
  • Calo, L. A., Pagnin, E., Davis, P. A., Semplicini, A., Nicolai, R., Calvani, M., and Pessina, A. C. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int.J Cardiol. 2-8-2006;107(1):54-60. View abstract.
  • Cao, Y., Wang, Y. X., Liu, C. J., Wang, L. X., Han, Z. W., and Wang, C. B. Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. Clin Invest Med. 2009;32(1):E13-E19. View abstract.
  • Carlsson, M., Forsberg, E., and Thorne, A. Observations during L-carnitine infusion in two long-term critically ill patients. Clin Physiol 1984;4(4):363-365. View abstract.
  • Carroll, J. K., Kohli, S., Mustian, K. M., Roscoe, J. A., and Morrow, G. R. Pharmacologic treatment of cancer-related fatigue. Oncologist. 2007;12 Suppl 1:43-51. View abstract.
  • Caruso U, Cravotto E, Tisone G, and et al. Long-term treatment with L-carnitine in uremic patients undergoing chronic hemodialysis: effects on the lipid pattern. Current Therapeutic Reserch 1983;33(6):1098-1104.
  • Caruso U, Leone L Cravotto E Nava D. Effects of L-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: A pilot study. Dial Transplant 1998;27:498-506.
  • Casciani CU, Caruso U, Cravotto E, and et al. Beneficial effects of L-carnitine in post dialysis syndrome. Curr Ther res, Clin exp 1982;32(11):116-127.
  • Casciani, C. U., Caruso, U., Cravotto, E., Corsi, M., Pola, P., Savi, L., and Grilli, M. Effect of L-carnitine on lipid pattern in haemodialysis. Lancet 12-13-1980;2(8207):1309-1310. View abstract.
  • Casciani, C. U., Caruso, U., Cravotto, E., D'Iddio, S., Corsi, M., Pola, P., Savi, L., and Grilli, M. L-carnitine in haemodialysed patients. Changes in lipid pattern. Arzneimittelforschung 1982;32(3):293-297. View abstract.
  • Cavallini, G., Ferraretti, A. P., Gianaroli, L., Biagiotti, G., and Vitali, G. Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele-associated oligoasthenospermia. J Androl 2004;25(5):761-770. View abstract.
  • Cetinkaya, A., Bulbuloglu, E., Kantarceken, B., Ciralik, H., Kurutas, E. B., Buyukbese, M. A., and Gumusalan, Y. Effects of L-carnitine on oxidant/antioxidant status in acetic acid-induced colitis. Dig.Dis Sci 2006;51(3):488-494. View abstract.
  • Cha, Y. S., Choi, S. K., Suh, H., Lee, S. N., Cho, D., and Li, K. Effects of carnitine coingested caffeine on carnitine metabolism and endurance capacity in athletes. J Nutr Sci Vitaminol.(Tokyo) 2001;47(6):378-384. View abstract.
  • Chan, A., Paskavitz, J., Remington, R., Rasmussen, S., and Shea, T. B. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am.J Alzheimers.Dis Other Demen. 12-20-2008;23(6):571-585. View abstract.
  • Chan, A., Remington, R., Kotyla, E., Lepore, A., Zemianek, J., and Shea, T. B. A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. J.Nutr.Health Aging 2010;14(3):224-230. View abstract.
  • Chan, Y. C., Tse, M. L., and Lau, F. L. Two cases of valproic acid poisoning treated with L-carnitine. Hum.Exp.Toxicol. 2007;26(12):967-969. View abstract.
  • Chao, H. H., Chen, C. H., Liu, J. C., Lin, J. W., Wong, K. L., and Cheng, T. H. L-Carnitine attenuates angiotensin II-induced proliferation of cardiac fibroblasts: role of NADPH oxidase inhibition and decreased sphingosine-1-phosphate generation. J Nutr.Biochem. 2010;21(7):580-588. View abstract.
  • Chazot, C., Blanc, C., Hurot, J. M., Charra, B., Jean, G., and Laurent, G. Nutritional effects of carnitine supplementation in hemodialysis patients. Clin Nephrol 2003;59(1):24-30. View abstract.
  • Chen, J. C., Tsai, T. C., Liu, C. S., and Lu, C. T. Acute hearing loss in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol.Taiwan. 2007;16(3):168-172. View abstract.
  • Chen, X. F., Li, Z., Ping, P., Dai, J. C., Zhang, F. B., and Shang, X. J. [Efficacy of natural vitamin E on oligospermia and asthenospermia: a prospective multi-centered randomized controlled study of 106 cases]. Zhonghua Nan.Ke.Xue 2012;18(5):428-431. View abstract.
  • Cheng, H. J. and Chen, T. [Clinical efficacy of combined L-carnitine and acetyl-L-carnitine on idiopathic asthenospermia]. Zhonghua Nan.Ke.Xue. 2008;14(2):149-151. View abstract.
  • Cipolli, C. and Chiari, G. [Effects of L-acetylcarnitine on mental deterioration in the aged: initial results]. Clin Ter 3-31-1990;132(6 Suppl):479-510. View abstract.
  • Colon-Soto, M., Peredo, R. A., and Vila, L. M. Systemic lupus erythematosus after mesotherapy with acetyl-L-carnitine. J Clin Rheumatol. 2006;12(5):261-262. View abstract.
  • Corbucci, G. G., Melis, A., Piga, M., Marchionni, A., and Calvani, M. Influence of acetyl-carnitine on some mitochondrial enzymic activities in the human cerebral tissue in conditions of acute hypoxia. Int J Tissue React. 1992;14(4):183-194. View abstract.
  • Corbucci, G. G., Menichetti, A., Cogliatti, A., Nicoli, P., and Ruvolo, C. Metabolic aspects of acute tissue hypoxia during extracorporeal circulation and their modification induced by L-carnitine treatment. Int J Clin Pharmacol Res 1992;12(3):149-157. View abstract.
  • Corsi, C., Pollastri, M., Marrapodi, E., Leanza, D., Giordano, S., and D'Iddio, S. L-propionylcarnitine effect on postexercise and postischemic hyperemia in patients affected by peripheral vascular disease. Angiology 1995;46(8):705-713. View abstract.
  • Costa, M., Canale, D., Filicori, M., D'lddio, S., and Lenzi, A. L-carnitine in idiopathic asthenozoospermia: a multicenter study. Italian Study Group on Carnitine and Male Infertility. Andrologia 1994;26(3):155-159. View abstract.
  • Coto V, D'Alessandro L, Grattarola G, and et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs Exptl Clin Res 1992;18(1):29-36.
  • Crentsil, V. Mechanistic contribution of carnitine deficiency to geriatric frailty. Ageing Res.Rev. 2010;9(3):265-268. View abstract.
  • Crill, C. M., Christensen, M. L., Storm, M. C., and Helms, R. A. Relative bioavailability of carnitine supplementation in premature neonates. JPEN J Parenter.Enteral Nutr. 2006;30(5):421-425. View abstract.
  • Crill, C. M., Storm, M. C., Christensen, M. L., Hankins, C. T., Bruce, Jenkins M., and Helms, R. A. Carnitine supplementation in premature neonates: effect on plasma and red blood cell total carnitine concentrations, nutrition parameters and morbidity. Clin Nutr. 2006;25(6):886-896. View abstract.
  • Cruciani, R. A., Dvorkin, E., Homel, P., Culliney, B., Malamud, S., Lapin, J., Portenoy, R. K., and Esteban-Cruciani, N. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom.Manage. 2009;37(4):622-631. View abstract.
  • Cruciani, R. A., Dvorkin, E., Homel, P., Culliney, B., Malamud, S., Shaiova, L., Fleishman, S., Lapin, J., Klein, E., Lesage, P., Portenoy, R., and Esteban-Cruciani, N. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N.Y.Acad.Sci 2004;1033:168-176. View abstract.
  • Csiky, B., Nyul, Z., Toth, G., Wittmann, I., Melegh, B., Rauh, M., Rascher, W., and Sulyok, E. L-carnitine supplementation and adipokines in patients with end-stage renal disease on regular hemodialysis. Exp.Clin Endocrinol.Diabetes 2010;118(10):735-740. View abstract.
  • Cucinotta D, Passeri M, Ventura S, and et al. Multicenter clinical placebo-controlled study with acetyl-L-carnitine in the treatment of mildly demented elderly patients. Drug Dev Res 1988;14:213-216.
  • Cui, G., Xu, W. H., and Wu.G.P. Effects of wuzi yanzong liquids combing with L-carnitine on oligospermia and asthenospermia. J.HainanMed.College 2011;17(3):347-349.
  • Curran, J. S., Williams, P. R., Kanarek, K. S., Novak, M., and Monkus, E. F. An evaluation of orally supplemented L-carnitine in premature infants receiving Intralipid 20%. Acta Chir Scand Suppl 1983;517:157-164. View abstract.
  • Cuturic, M., Abramson, R. K., Moran, R. R., and Hardin, J. W. Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review. J Psychiatr.Pract. 2010;16(1):5-14. View abstract.
  • Dal Negro R, Pomari G, Zoccatelli O, and et al. Changes in physical performance of untrained volunteers: effects of L-carnitine. Clinical Trials Journal 1986;23(4):242-248.
  • Dal Negro, R., Turco, P., Pomari, C., and De Conti, F. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol. 1988;26(5):269-272. View abstract.
  • de Lira-Garcia, C., Souto-Gallardo, M., Bacardi-Gascon, M., and Jimenez-Cruz, A. [A systematic review of the effectiveness of alternative weight-loss products' ingredients]. Rev.Salud Publica (Bogota.) 2008;10(5):818-830. View abstract.
  • De Marchi, S., Zecchetto, S., Rigoni, A., Prior, M., Fondrieschi, L., Scuro, A., Rulfo, F., and Arosio, E. Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia. Cardiovasc.Drugs Ther 2012;26(5):401-408. View abstract.
  • De Pasquale, B., Righetti, G., and Menotti, A. [L-carnitine for the treatment of acute myocardial infarct]. Cardiologia 1990;35(7):591-596. View abstract.
  • De Ritis G, Picardo S, Brancadoro D, and et al. The effect of carnitine in patients using artificial pacemakers. Current Therapeutic Research 1989;46(6):1027-1033.
  • De Simone C, Catania S, Trinchieri V, and et al. Amelioration of the depression of HIV-infected subjects with L-acetyl carnitine therapy. J Drug Dev 1988;1(3):163-166.
  • De Simone, C., Tzantzoglou, S., Famularo, G., Moretti, S., Paoletti, F., Vullo, V., and Delia, S. High dose L-carnitine improves immunologic and metabolic parameters in AIDS patients. Immunopharmacol.Immunotoxicol. 1993;15(1):1-12. View abstract.
  • De Vecchi, A. F., Arduini, A., Di, Liberato L., and Bonomini, M. [L-carnitine in peritoneal dialysis]. G.Ital.Nefrol. 2011;28(4):393-400. View abstract.
  • Dealberto, M. J. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int.Clin Psychopharmacol. 2007;22(6):330-337. View abstract.
  • Decombaz, J., Deriaz, O., Acheson, K., Gmuender, B., and Jequier, E. Effect of L-carnitine on submaximal exercise metabolism after depletion of muscle glycogen. Med Sci Sports Exerc. 1993;25(6):733-740. View abstract.
  • DeFelice SL and Gilgore SG. The antagonistic effect of carnitine in hyperthyroidism. Preliminary report. Journal of New Drugs 1966;6(6):351-353.
  • del Olmo, J. A., Castillo, M., Rodrigo, J. M., Aparisi, L., Serra, M. A., Wassel, A., and Bixquert, M. Effect of L-carnitine upon ammonia tolerance test in cirrhotic patients. Adv Exp Med Biol 1990;272:197-208. View abstract.
  • Demeyere, R., Lormans, P., Weidler, B., Minten, J., Van Aken, H., and Flameng, W. Cardioprotective effects of carnitine in extensive aortocoronary bypass grafting: a double-blind, randomized, placebo-controlled clinical trial. Anesth.Analg. 1990;71(5):520-528. View abstract.
  • Derosa, G., Cicero, A. F., Gaddi, A., Mugellini, A., Ciccarelli, L., and Fogari, R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003;25(5):1429-1439. View abstract.
  • Derosa, G., Maffioli, P., Ferrari, I., D'Angelo, A., Fogari, E., Palumbo, I., Randazzo, S., and Cicero, A. F. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam.Clin Pharmacol 2011;25(5):642-651. View abstract.
  • Derosa, G., Maffioli, P., Ferrari, I., D'Angelo, A., Fogari, E., Palumbo, I., Randazzo, S., and Cicero, A. F. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr.J 2010;57(9):777-786. View abstract.
  • Derosa, G., Maffioli, P., Salvadeo, S. A., Ferrari, I., Gravina, A., Mereu, R., D'Angelo, A., Palumbo, I., Randazzo, S., and Cicero, A. F. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism 2011;60(3):421-429. View abstract.
  • Derosa, G., Maffioli, P., Salvadeo, S. A., Ferrari, I., Gravina, A., Mereu, R., D'Angelo, A., Palumbo, I., Randazzo, S., and Cicero, A. F. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern.Med 2010;49(16):1717-1725. View abstract.
  • Desbree, A., Houdon, L., Touati, G., Djemili, S., Choker, G., and Flodrops, H. [EBV infection revealing a long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency in a 3-year-old boy]. Arch.Pediatr. 2011;18(1):18-22. View abstract.
  • Digiesi, V., Palchetti, R., and Cantini, F. [The benefits of L-carnitine therapy in essential arterial hypertension with diabetes mellitus type II]. Minerva Med 1989;80(3):227-231. View abstract.
  • DiMauro, S. and Hirano, M. Mitochondrial DNA Deletion Syndromes. In: Pagon, R. A., Bird, T. D., Dolan, C. R., Stephens, K., and Adam, M. P. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle;1993. View abstract.
  • Dimitriadis, F., Tsambalas, S., Tsounapi, P., Kawamura, H., Vlachopoulou, E., Haliasos, N., Gratsias, S., Watanabe, T., Saito, M., Miyagawa, I., and Sofikitis, N. Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU.Int. 2010;106(8):1181-1185. View abstract.
  • DiNicolantonio, J. J., Lavie, C. J., Fares, H., Menezes, A. R., and O'Keefe, J. H. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013;88(6):544-551. View abstract.
  • Dokmeci, D., Inan, M., Basaran, U. N., Yalcin, O., Aydogdu, N., Turan, F. N., and Uz, Y. H. Protective effect of L-carnitine on testicular ischaemia-reperfusion injury in rats. Cell Biochem.Funct. 2007;25(6):611-618. View abstract.
  • Donnelly, C. T., Hameed, A. B., Abdenur, J. E., and Wing, D. A. Carnitine deficiency in pregnancy. Obstet.Gynecol. 2007;110(2 Pt 2):480-482. View abstract.
  • Dragan, A. M., Vasiliu, D., Eremia, N. M., and Georgescu, E. Studies concerning some acute biological changes after endovenous administration of 1 g l-carnitine, in elite athletes. Physiologie. 1987;24(4):231-234. View abstract.
  • Dragan, G. I., Vasiliu, A., Georgescu, E., and Dumas, I. Studies concerning chronic and acute effects of L-carnitine on some biological parameters in elite athletes. Physiologie. 1987;24(1):23-28. View abstract.
  • Dragan, I. G., Vasiliu, A., Georgescu, E., and Eremia, N. Studies concerning chronic and acute effects of L-carnitina in elite athletes. Physiologie. 1989;26(2):111-129. View abstract.
  • Duranay, M., Akay, H., Yilmaz, F. M., Senes, M., Tekeli, N., and Yucel, D. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol.Dial Transplant 2006;21(11):3211-3214. View abstract.
  • Dutta, A., Ray, K., Singh, V. K., Vats, P., Singh, S. N., and Singh, S. B. L-carnitine supplementation attenuates intermittent hypoxia-induced oxidative stress and delays muscle fatigue in rats. Exp.Physiol 2008;93(10):1139-1146. View abstract.
  • Eidi, M., Pouyan, O., Shahmohammadi, P., Saeidi, H., Bahar, M., and Eidi, A. Effect of L-carnitine supplement on semen parameters in men with idiopathic infertility. J.Med.Sci.J.Islamic Azad Univ. 2009;19(1):Pe11-Pe15.
  • El Beshlawy, A., Abd, El Raouf, Mostafa, F., Talaat, M., Isma'eel, H., Aoun, E., Hoffbrand, A. V., and Taher, A. Diastolic dysfunction and pulmonary hypertension in sickle cell anemia: is there a role for L-carnitine treatment? Acta Haematol. 2006;115(1-2):91-96. View abstract.
  • El Beshlawy, A., Mohtar, G., Abd El, Ghafar E., Abd El Dayem, S. M., El Sayed, M. H., Aly, A. A., and Farok, M. Assessment of puberty in relation to L-carnitine and hormonal replacement therapy in beta-thalassemic patients. J Trop.Pediatr. 2008;54(6):375-381. View abstract.
  • El-Beshlawy, A., El, Accaoui R., Abd El-Sattar, M., Gamal El-Deen, M. H., Youssry, I., Shaheen, N., Hamdy, M., El-Ghamrawy, M., and Taher, A. Effect of L-carnitine on the physical fitness of thalassemic patients. Ann.Hematol. 2007;86(1):31-34. View abstract.
  • El-Beshlawy, A., Youssry, I., El-Saidi, S., El, Accaoui R., Mansi, Y., Makhlouf, A., and Taher, A. Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. Pediatr.Hematol.Oncol. 2008;25(8):734-743. View abstract.
  • El-Metwally, T. H., Hamed, E. A., Ahmad, A. R., and Mohamed, N. A. Dyslipidemia, oxidative stress and cardiac dysfunction in children with chronic renal failure: effects of L-carnitine supplementation. Ann.Saudi.Med. 2003;23(5):270-277. View abstract.
  • Ellaway, C. J., Peat, J., Williams, K., Leonard, H., and Christodoulou, J. Medium-term open label trial of L-carnitine in Rett syndrome. Brain Dev. 2001;23 Suppl 1:S85-S89. View abstract.
  • Elmslie, J. L., Porter, R. J., Joyce, P. R., Hunt, P. J., and Mann, J. I. Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar.Disord. 2006;8(5 Pt 1):503-507. View abstract.
  • Erbas, H., Aydogdu, N., Usta, U., and Erten, O. Protective role of carnitine in breast cancer via decreasing arginase activity and increasing nitric oxide. Cell Biol.Int. 2007;31(11):1414-1419. View abstract.
  • Eroglu, H., Senel, O., and Guzel, N. A. Effects of acute L-carnitine intake on metabolic and blood lactate levels of elite badminton players. Neuro.Endocrinol.Lett. 2008;29(2):261-266. View abstract.
  • Evangelista, M., Koverech, A., Messano, M., and Pescosolido, N. Comparison of three lubricant eye drop solutions in dry eye patients. Optom.Vis.Sci 2011;88(12):1439-1444. View abstract.
  • Evans, J. D., Jacobs, T. F., and Evans, E. W. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann.Pharmacother. 2008;42(11):1686-1691. View abstract.
  • Fagher, B., Cederblad, G., Eriksson, M., Monti, M., Moritz, U., Nilsson-Ehle, P., and Thysell, H. L-carnitine and haemodialysis: double blind study on muscle function and metabolism and peripheral nerve function. Scand.J Clin Lab Invest 1985;45(2):169-178. View abstract.
  • Fagher, B., Cederblad, G., Monti, M., Olsson, L., Rasmussen, B., and Thysell, H. Carnitine and left ventricular function in haemodialysis patients. Scand.J Clin Lab Invest 1985;45(3):193-198. View abstract.
  • Fagher, B., Thysell, H., Nilsson-Ehle, P., Monti, M., Olsson, L., Eriksson, M., Lindstedt, S., and Lindholm, T. The effect of D,L-carnitine supplementation on muscle metabolism, neuropathy, cardiac and hepatic function in hemodialysis patients. A pilot study. Acta Med Scand 1982;212(3):115-120. View abstract.
  • Famularo, G., Moretti, S., Alesse, E., Trinchieri, V., Angelucci, A., Santini, G., Cifone, G., and De, Simone C. Reduction of glutamate levels in HIV-infected subjects treated with acetylcarnitine. J NeuroAIDS. 1999;2(2):65-73. View abstract.
  • Fan, J. P., Kim, H. S., and Han, G. D. Induction of apoptosis by L-carnitine through regulation of two main pathways in Hepa1c1c 7 cells. Amino.Acids 2009;36(2):365-372. View abstract.
  • Faria, C. C., Mota, J. F., Paula Ravagnani, F. C., and Burini, R. C. [The supplementation of L-carnitine does not promote alterations in the resting metabolic rate and in the use of energetic substrates in physically active individuals]. Arq Bras.Endocrinol.Metabol. 2010;54(1):37-44. View abstract.
  • Fatouros, I. G., Douroudos, I., Panagoutsos, S., Pasadakis, P., Nikolaidis, M. G., Chatzinikolaou, A., Sovatzidis, A., Michailidis, Y., Jamurtas, A. Z., Mandalidis, D., Taxildaris, K., and Vargemezis, V. Effects of L-carnitine on oxidative stress responses in patients with renal disease. Med.Sci Sports Exerc. 2010;42(10):1809-1818. View abstract.
  • Feillet, F., Ogier, H., Cheillan, D., Aquaviva, C., Labarthe, F., Baruteau, J., Chabrol, B., de, Lonlay P., Valayanopoulos, V., Garnotel, R., Dobbelaere, D., Briand, G., Jeannesson, E., Vassault, A., and Vianey-Saban, C. [Medium-chain acyl-CoA-dehydrogenase (MCAD) deficiency: French consensus for neonatal screening, diagnosis, and management]. Arch.Pediatr 2012;19(2):184-193. View abstract.
  • Feinfeld, D. A., Kurian, P., Cheng, J. T., Dilimetin, G., Arriola, M. R., Ward, L., Manis, T., and Carvounis, C. P. Effect of oral L-carnitine on serum myoglobin in hemodialysis patients. Ren Fail. 1996;18(1):91-96. View abstract.
  • Fenkci, S. M., Fenkci, V., Oztekin, O., Rota, S., and Karagenc, N. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Hum.Reprod. 2008;23(7):1602-1606. View abstract.
  • Fernandez, C. and Proto, C. [L-carnitine in the treatment of chronic myocardial ischemia. An analysis of 3 multicenter studies and a bibliographic review]. Clin Ter. 1992;140(4):353-377. View abstract.
  • Ferrari R, Cucchini F, Dilisa F, and et al. The effect of L-carnitine (carnitene) on myocardial metabolism of patients with coronary artery disease. Clin Trial J 1984;21:40-58.
  • Fietta, P. and Manganelli, P. Carnitine: a therapeutic option for childhood psoriatic onycho-pachydermo-periostitis (POPP). Clin Rheumatol. 2007;26(1):93-94. View abstract.
  • Filipek, P. A., Juranek, J., Nguyen, M. T., Cummings, C., and Gargus, J. J. Relative carnitine deficiency in autism. J Autism Dev.Disord. 2004;34(6):615-623. View abstract.
  • Foitzik, K., Hoting, E., Heinrich, U., Tronnier, H., and Paus, R. Indications that topical L-carnitin-L-tartrate promotes human hair growth in vivo. J Dermatol.Sci 2007;48(2):141-144. View abstract.
  • Footitt, E. J., Stafford, J., Dixon, M., Burch, M., Jakobs, C., Salomons, G. S., and Cleary, M. A. Use of a long-chain triglyceride-restricted/medium-chain triglyceride-supplemented diet in a case of malonyl-CoA decarboxylase deficiency with cardiomyopathy. J Inherit.Metab Dis 6-15-2010; View abstract.
  • Fornasini, G., Upton, R. N., and Evans, A. M. A pharmacokinetic model for L-carnitine in patients receiving haemodialysis. Br.J Clin Pharmacol 2007;64(3):335-345. View abstract.
  • Fortin, G., Yurchenko, K., Collette, C., Rubio, M., Villani, A. C., Bitton, A., Sarfati, M., and Franchimont, D. L-carnitine, a diet component and organic cation transporter OCTN ligand, displays immunosuppressive properties and abrogates intestinal inflammation. Clin Exp.Immunol. 2009;156(1):161-171. View abstract.
  • Fujiwara, M., Nakano, T., Tamoto, S., Yamada, Y., Fukai, M., Takada, K., Ashida, H., Shimada, T., Ishihara, T., and Seki, I. [Effect of L-carnitine in patients with ischemic heart disease]. J Cardiol 1991;21(2):493-504. View abstract.
  • Fulgente T, Onofrj M Del Re ML et al. Laevo-acetylcarnitine (Nicetile registered) treatment of senile depression. Clin Trials J 1990;27:155-163.
  • Galvano, F., Li, Volti G., Malaguarnera, M., Avitabile, T., Antic, T., Vacante, M., and Malaguarnera, M. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert.Opin.Pharmacother. 2009;10(12):1875-1882. View abstract.
  • Ganio, M. S., Klau, J. F., Lee, E. C., Yeargin, S. W., McDermott, B. P., Buyckx, M., Maresh, C. M., and Armstrong, L. E. Effect of various carbohydrate-electrolyte fluids on cycling performance and maximal voluntary contraction. Int J Sport Nutr Exerc.Metab 2010;20(2):104-114. View abstract.
  • Gecele M, Francesetti G, and Meluzzi A. Acetyl-L-carnitine in aged subjects with major depression: clinical efficacy and effects on the circadian rhythm of cortisol. Dementia 1991;2(6):333-337.
  • Geier, D. A., Kern, J. K., Davis, G., King, P. G., Adams, J. B., Young, J. L., and Geier, M. R. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med.Sci Monit. 2011;17(6):I15-I23. View abstract.
  • Genazzani, A. D., Lanzoni, C., Ricchieri, F., Santagni, S., Rattighieri, E., Chierchia, E., Monteleone, P., and Jasonni, V. M. Acetyl-L-carnitine (ALC) administration positively affects reproductive axis in hypogonadotropic women with functional hypothalamic amenorrhea. J Endocrinol.Invest 2011;34(4):287-291. View abstract.
  • Genger, H., Enzelsberger, H., and Salzer, H. [Carnitine in therapy of placental insufficiency--initial experiences]. Z Geburtshilfe Perinatol. 1988;192(4):155-157. View abstract.
  • Gentile, V., Antonini, G., Antonella, Bertozzi M., Dinelli, N., Rizzo, C., Ashraf, Virmani M., and Koverech, A. Effect of propionyl-L-carnitine, L-arginine and nicotinic acid on the efficacy of vardenafil in the treatment of erectile dysfunction in diabetes. Curr Med Res Opin. 2009;25(9):2223-2228. View abstract.
  • Gesuete, V., Ragni, L., and Picchio, F. M. [The "big heart" of carnitine]. G.Ital.Cardiol.(Rome) 2010;11(9):703-705. View abstract.
  • Giamberardino, M. A., Dragani, L., Valente, R., di Lisa, F., Saggini, R., and Vecchiet, L. Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. Int J Sports Med 1996;17(5):320-324. View abstract.
  • Giammusso B, Morgia G, Spampinato A, and et al. Improved pallesthetic sensitivity of pudendal nerve in impotent diabetic patients treated with acetyl-L-carnitine. Acta Urol Ital 1996;10(3):185-187.
  • Gibault, J. P., Frey, A., Guiraud, M., Schirardin, H., Bouletreau, P., and Bach, A. C. Effects of L-carnitine infusion on intralipid clearance and utilization. Study carried out in septic patients of an intensive care unit. JPEN J Parenter.Enteral Nutr 1988;12(1):29-34. View abstract.
  • Goetz, C. G., Tanner, C. M., Cohen, J. A., Thelen, J. A., Carroll, V. S., Klawans, H. L., and Fariello, R. G. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord. 1990;5(3):263-265. View abstract.
  • Goldenberg, N. A., Krantz, M. J., and Hiatt, W. R. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vasc.Med 2012;17(3):145-154. View abstract.
  • Golper, T. A., Wolfson, M., Ahmad, S., Hirschberg, R., Kurtin, P., Katz, L. A., Nicora, R., Ashbrook, D., and Kopple, J. D. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int 1990;38(5):904-911. View abstract.
  • Gonzalez-Ortiz, M., Hernandez-Gonzalez, S. O., Hernandez-Salazar, E., and Martinez-Abundis, E. Effect of oral L-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients. Ann.Nutr.Metab 2008;52(4):335-338. View abstract.
  • Gorostiaga, E. M., Maurer, C. A., and Eclache, J. P. Decrease in respiratory quotient during exercise following L-carnitine supplementation. Int J Sports Med 1989;10(3):169-174. View abstract.
  • Gramignano, G., Lusso, M. R., Madeddu, C., Massa, E., Serpe, R., Deiana, L., Lamonica, G., Dessi, M., Spiga, C., Astara, G., Maccio, A., and Mantovani, G. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 2006;22(2):136-145. View abstract.
  • Grandis, D. D. Tolerability and efficacy of L-acetylcarnitine in patients with peripheral neuropathies: a short-term, open multicentre study. Clin Drug Investig. 1998;15(2):73-79. View abstract.
  • Graziano F, Renato B, Catalano V, and et al. Potential role of levocarnitine supplementation for treatment of chemotherapy-induced fatigue in non-anemic cancer patients. (pre-publication author's copy, via correspondence) 2002;1-14.
  • Greco, A. V., Mingrone, G., Bianchi, M., and Ghirlanda, G. Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double blind trial versus placebo. Drugs Exp Clin Res 1992;18(2):69-80. View abstract.
  • Greig, C., Finch, K. M., Jones, D. A., Cooper, M., Sargeant, A. J., and Forte, C. A. The effect of oral supplementation with L-carnitine on maximum and submaximum exercise capacity. Eur J Appl Physiol Occup.Physiol 1987;56(4):457-460. View abstract.
  • Guan, Y., Zheng, X. M., Yang, Z. W., and Li, S. W. [Protective effects of L-carnitine upon testicular ischemia-reperfusion damage in rats]. Zhonghua Yi.Xue.Za Zhi. 7-14-2009;89(26):1858-1861. View abstract.
  • Guarnieri, G. F., Ranieri, F., Toigo, G., Vasile, A., Ciman, M., Rizzoli, V., Moracchiello, M., and Campanacci, L. Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. Am J Clin Nutr 1980;33(7):1489-1492. View abstract.
  • Guevara-Campos, J., Gonzalez-Guevara, L., Parada, Y., and Urbaez-Cano, J. [Infantile encephalopathy associated with the MELAS A3243G mutation. Case report]. Invest Clin 2007;48(2):243-248. View abstract.
  • Guideri, F., Acampa, M., Hayek, Y., and Zappella, M. Effects of acetyl-L-carnitine on cardiac dysautonomia in Rett syndrome: prevention of sudden death? Pediatr Cardiol 2005;26(5):574-577. View abstract.
  • Gunal, A. I., Celiker, H., Donder, E., and Gunal, S. Y. The effect of L-carnitine on insulin resistance in hemodialysed patients with chronic renal failure. J Nephrol. 1999;12(1):38-40. View abstract.
  • Gurlek, A., Tutar, E., Akcil, E., Dincer, I., Erol, C., Kocaturk, P. A., and Oral, D. The effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy. Eur J Heart Fail. 2000;2(2):189-193. View abstract.
  • Gwak, J. H., Lee, J. H., Lee, S. J., Park, H. W., Kim, Y., and Hyun, Y. J. The effect of L-carnitine and isoflavone supplementation on weight reduction and visceral fat accumulation in overweight women. Korean J.Nutrition 2007;40(7):630-638.
  • Hakeshzadeh, F., Tabibi, H., Ahmadinejad, M., Malakoutian, T., and Hedayati, M. Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. Ren Fail. 2010;32(9):1109-1114. View abstract.
  • Harper, P., Elwin, C. E., and Cederblad, G. Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. Eur J Clin Pharmacol 1988;35(5):555-562. View abstract.
  • Hathcock, J. N. and Shao, A. Risk assessment for carnitine. Regul.Toxicol.Pharmacol 2006;46(1):23-28. View abstract.
  • Hauck, E. W., Diemer, T., Schmelz, H. U., and Weidner, W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur.Urol. 2006;49(6):987-997. View abstract.
  • Head, E., Nukala, V. N., Fenoglio, K. A., Muggenburg, B. A., Cotman, C. W., and Sullivan, P. G. Effects of age, dietary, and behavioral enrichment on brain mitochondria in a canine model of human aging. Exp.Neurol. 2009;220(1):171-176. View abstract.
  • Heil, S. G., Hogeveen, M., Kluijtmans, L. A., van Dijken, P. J., van de Berg, G. B., Blom, H. J., and Morava, E. Marfanoid features in a child with combined methylmalonic aciduria and homocystinuria (CblC type). J Inherit.Metab Dis 2007;30(5):811. View abstract.
  • Heller, W., Musil, H. E., Gaebel, G., Hempel, V., Krug, W., and Kohn, H. J. [Effect of L-carnitine on post-stress metabolism in surgical patients]. Infusionsther.Klin.Ernahr. 1986;13(6):268-276. View abstract.
  • Helms, R. A., Mauer, E. C., Hay, W. W., Jr., Christensen, M. L., and Storm, M. C. Effect of intravenous L-carnitine on growth parameters and fat metabolism during parenteral nutrition in neonates. JPEN J Parenter.Enteral Nutr 1990;14(5):448-453. View abstract.
  • Helms, R. A., Whitington, P. F., Mauer, E. C., Catarau, E. M., Christensen, M. L., and Borum, P. R. Enhanced lipid utilization in infants receiving oral L-carnitine during long-term parenteral nutrition. J Pediatr 1986;109(6):984-988. View abstract.
  • Heringer, J., Boy, S. P., Ensenauer, R., Assmann, B., Zschocke, J., Harting, I., Lucke, T., Maier, E. M., Muhlhausen, C., Haege, G., Hoffmann, G. F., Burgard, P., and Kolker, S. Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann.Neurol. 2010;68(5):743-752. View abstract.
  • Herrmann, W. M., Dietrich, B., and Hiersemenzel, R. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome. Int J Clin Pharmacol Res 1990;10(1-2):81-84. View abstract.
  • Hiatt, W. R., Creager, M. A., Amato, A., and Brass, E. P. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease. J Cardiopulm.Rehabil.Prev. 2011;31(2):125-132. View abstract.
  • Hlais, S., Reslan, D. R., Sarieddine, H. K., Nasreddine, L., Taan, G., Azar, S., and Obeid, O. A. Effect of lysine, vitamin B(6), and carnitine supplementation on the lipid profile of male patients with hypertriglyceridemia: a 12-week, open-label, randomized, placebo-controlled trial. Clin Ther 2012;34(8):1674-1682. View abstract.
  • Ho, J. Y., Kraemer, W. J., Volek, J. S., Fragala, M. S., Thomas, G. A., Dunn-Lewis, C., Coday, M., Hakkinen, K., and Maresh, C. M. l-Carnitine l-tartrate supplementation favorably affects biochemical markers of recovery from physical exertion in middle-aged men and women. Metabolism 2010;59(8):1190-1199. View abstract.
  • Hoffman, J. R., Ratamess, N. A., Gonzalez, A., Beller, N. A., Hoffman, M. W., Olson, M., Purpura, M., and Jager, R. The effects of acute and prolonged CRAM supplementation on reaction time and subjective measures of focus and alertness in healthy college students. J Int.Soc.Sports Nutr. 2010;7:39. View abstract.
  • Holzhauer, P. Casuistry: medical nutrition intervention with specific micronutrient and exercise therapy in pancreatic cancer. Zeitschrift für Orthomolekulare Medizin 2009;7(3):22-24.
  • Hooshmand, S., Balakrishnan, A., Clark, R. M., Owen, K. Q., Koo, S. I., and Arjmandi, B. H. Dietary l-carnitine supplementation improves bone mineral density by suppressing bone turnover in aged ovariectomized rats. Phytomedicine. 2008;15(8):595-601. View abstract.
  • Horvath, G. A., Davidson, A. G., Stockler-Ipsiroglu, S. G., Lillquist, Y. P., Waters, P. J., Olpin, S., Andresen, B. S., Palaty, J., Nelson, J., and Vallance, H. Newborn screening for MCAD deficiency: experience of the first three years in British Columbia, Canada. Can.J Public Health 2008;99(4):276-280. View abstract.
  • Hsieh, C. T., Hwu, W. L., Huang, Y. T., Huang, A. C., Wang, S. F., Hu, M. H., and Chien, Y. H. Early detection of glutaric aciduria type I by newborn screening in Taiwan. J Formos.Med.Assoc. 2008;107(2):139-144. View abstract.
  • Huang, W. W., Wang, M. Y., Shi, H. M., Peng, Y., Peng, C. S., Zhang, M., Li, Y., Lu, J., and Li, X. B. Comparative study of bioactive constituents in crude and processed Glycyrrhizae radix and their respective metabolic profiles in gastrointestinal tract in vitro by HPLC-DAD and HPLC-ESI/MS analyses. Arch.Pharm Res 2012;35(11):1945-1952. View abstract.
  • Huang, Y., Huang, L. C., and Zhan, F. Clinical analysis of therapeutic effect of levocarnitine on dialysis patients. China Tropical Med 2007;7(5):753-754.
  • Huidekoper, H. H., Schneider, J., Westphal, T., Vaz, F. M., Duran, M., and Wijburg, F. A. Prolonged moderate-intensity exercise without and with L-carnitine supplementation in patients with MCAD deficiency. J Inherit.Metab Dis 2006;29(5):631-636. View abstract.
  • Ishii, K., Komaki, H., Ohkuma, A., Nishino, I., Nonaka, I., and Sasaki, M. Central nervous system and muscle involvement in an adolescent patient with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Brain Dev. 2010;32(8):669-672. View abstract.
  • Isidori, A. M., Pozza, C., Gianfrilli, D., and Isidori, A. Medical treatment to improve sperm quality. Reprod.Biomed.Online. 2006;12(6):704-714. View abstract.
  • Iyer, R. N., Khan, A. A., Gupta, A., Vajifdar, B. U., and Lokhandwala, Y. Y. L-carnitine moderately improves the exercise tolerance in chronic stable angina. J Assoc Physicians India 2000;48(11):1050-1052. View abstract.
  • Iyer, R., Gupta, A., Khan, A., Hiremath, S., and Lokhandwala, Y. Does left ventricular function improve with L-carnitine after acute myocardial infarction? J Postgrad Med 1999;45(2):38-41. View abstract.
  • Jacoba KG, Abarquez RF, Topacio GO, and et al. Effect of L-carnitine on the limitation of infarct size in one-month postmyocardial infarction cases. A multicentre, randomized, parallel, placebo-controlled trial. Clin Drug Invest 1996;11(2):90-96.
  • Jacobs, P. L. and Goldstein, E. R. Long-term glycine propionyl-l-carnitine supplemention and paradoxical effects on repeated anaerobic sprint performance. J Int.Soc.Sports Nutr. 2010;7:35. View abstract.
  • Jacobs, P. L., Goldstein, E. R., Blackburn, W., Orem, I., and Hughes, J. J. Glycine propionyl-L-carnitine produces enhanced anaerobic work capacity with reduced lactate accumulation in resistance trained males. J Int.Soc.Sports Nutr. 2009;6:9. View abstract.
  • Janiri, L., Martinotti, G., Tonioni, F., Ghelardini, C., Nicolai, R., Galeotti, N., Mosconi, L., Calvani, M., Bartolini, A., and Iannoni, E. Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome. Clin Neuropharmacol. 2009;32(1):35-40. View abstract.
  • Jimenez Caballero, P. E. and Marsal, Alonso C. [Type 1 glutaric aciduria: clinical and therapeutic implications]. Neurologia 2007;22(5):329-332. View abstract.
  • Jing, L., Li, W. M., Zhou, L. J., and Song, J. [L-carnitine and cardiac metabolism and remodeling indices in alcoholic cardiomyopathy]. Zhonghua Nei Ke.Za Zhi. 2008;47(11):934-937. View abstract.
  • Jing, L., Zhou, L. J., Li, W. M., Zhang, F. M., Yuan, L., Li, S., Song, J., and Sang, Y. Carnitine regulates myocardial metabolism by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha) in alcoholic cardiomyopathy. Med.Sci Monit. 2011;17(1):BR1-BR9. View abstract.
  • Jirillo, E., Altamura, M., Munno, I., Pellegrino, N. M., Sabato, R., Di Fabio, S., and De Simone, C. Effects of acetyl-L-carnitine oral administration on lymphocyte antibacterial activity and TNF-alpha levels in patients with active pulmonary tuberculosis. A randomized double blind versus placebo study. Immunopharmacol.Immunotoxicol. 1991;13(1-2):135-146. View abstract.
  • Jones, S., Reed, C. A., Vijay, S., Walter, J. H., and Morris, A. A. N-carbamylglutamate for neonatal hyperammonaemia in propionic acidaemia. J Inherit.Metab Dis 2008;31 Suppl 2:S219-S222. View abstract.
  • Jung, J., Eo, E., and Ahn, K. O. A case of hemoperfusion and L-carnitine management in valproic acid overdose. Am.J Emerg.Med. 2008;26(3):388-4. View abstract.
  • Kamikawa, T., Suzuki, Y., Kobayashi, A., Hayashi, H., Masumura, Y., Nishihara, K., Abe, M., and Yamazaki, N. Effects of L-carnitine on exercise tolerance in patients with stable angina pectoris. Jpn Heart J 1984;25(4):587-597. View abstract.
  • Kang, H. C., Kim, H. D., Lee, Y. M., and Han, S. H. Landau-Kleffner syndrome with mitochondrial respiratory chain-complex I deficiency. Pediatr.Neurol. 2006;35(2):158-161. View abstract.
  • Karahan, M., Cokseym, B., and Arts, S. The effect of L-carnitine supplementation on 1500 m running performance. Ovidius University Annals, Physical Education and Sport/Science, Movement and Health Series 2010;10(Suppl 2):504-507.
  • Karanth, J. and Jeevaratnam, K. Effect of carnitine supplementation on mitochondrial enzymes in liver and skeletal muscle of rat after dietary lipid manipulation and physical activity. Indian J Exp.Biol. 2010;48(5):503-510. View abstract.
  • Karanth, J. and Jeevaratnam, K. Effect of dietary lipid, carnitine and exercise on lipid profile in rat blood, liver and muscle. Indian J Exp.Biol. 2009;47(9):748-753. View abstract.
  • Karimi, M., Mohammadi, F., Behmanesh, F., Samani, S. M., Borzouee, M., Amoozgar, H., and Haghpanah, S. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. Eur.J Haematol. 1-1-2010;84(1):52-58. View abstract.
  • Katiyar, A. and Aaron, C. Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity. J Med.Toxicol. 2007;3(3):129-138. View abstract.
  • Kaviani, M., Nourshahi, M., and Shokoohi, F. The effects of acute L-carnitine administration on ventilatory breakpoint and exercise performance during incremental exercise. J.Mazandaran Univ.Med.Sci. 2009;19(73):43-50.
  • Kavukcu, S., Turkmen, M., Salman, S., Onvural, B., Oktay, G., Karaman, O., and Cevik, N. T. The effects of L-carnitine on respiratory function tests in children undergoing chronic hemodialysis. Turk.J Pediatr 1998;40(1):79-84. View abstract.
  • Kimmoun, A., Munagamage, G., Dessalles, N., Gerard, A., Feillet, F., and Levy, B. Unexpected awakening from comatose thyroid storm after a single intravenous injection of L-carnitine. Intensive Care Med. 2011;37(10):1716-1717. View abstract.
  • Kobayashi, A., Masumura, Y., and Yamazaki, N. L-carnitine treatment for congestive heart failure--experimental and clinical study. Jpn Circ.J 1992;56(1):86-94. View abstract.
  • Kobulia B, Chapichadze Z Andriadze G Machavariani P. Effects of carnitine on 6-month incidence of mortality and heart failure in patients with acute myocardial infarction. Ann Biomed Res Educ. 2002;2(3):240-243.
  • Kolker, S., Christensen, E., Leonard, J. V., Greenberg, C. R., Burlina, A. B., Burlina, A. P., Dixon, M., Duran, M., Goodman, S. I., Koeller, D. M., Muller, E., Naughten, E. R., Neumaier-Probst, E., Okun, J. G., Kyllerman, M., Surtees, R. A., Wilcken, B., Hoffmann, G. F., and Burgard, P. Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). J Inherit.Metab Dis 2007;30(1):5-22. View abstract.
  • Kolker, S., Garbade, S. F., Greenberg, C. R., Leonard, J. V., Saudubray, J. M., Ribes, A., Kalkanoglu, H. S., Lund, A. M., Merinero, B., Wajner, M., Troncoso, M., Williams, M., Walter, J. H., Campistol, J., Marti-Herrero, M., Caswill, M., Burlina, A. B., Lagler, F., Maier, E. M., Schwahn, B., Tokatli, A., Dursun, A., Coskun, T., Chalmers, R. A., Koeller, D. M., Zschocke, J., Christensen, E., Burgard, P., and Hoffmann, G. F. Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr.Res. 2006;59(6):840-847. View abstract.
  • Kosolcharoen T, Nappi J, Peduzzi P, and et al. Improved excercise tolerance after administration of carnitine. Current Therapeutic Research 1981;30(5):753-764.
  • Kotby, A. A., Yamamah, G. A. E., El-Baky, A. M. N. E. A., El-Kassas, G. M., and Elhalim, A. Z. A. Therapeutic evaluation of L-carnitine in Egyptian children with dilated cardiomyopathy. J.Med.Sci.(Pakistan) 2006;6(5):800-805.
  • Kraft, M., Kraft, K., Gartner, S., Mayerle, J., Simon, P., Weber, E., Schutte, K., Stieler, J., Koula-Jenik, H., Holzhauer, P., Grober, U., Engel, G., Muller, C., Feng, Y. S., Aghdassi, A., Nitsche, C., Malfertheiner, P., Patrzyk, M., Kohlmann, T., and Lerch, M. M. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. Nutr J 2012;11:52. View abstract.
  • Kumar, A., Singh, R. B., Saxena, M., Niaz, M. A., Josh, S. R., Chattopadhyay, P., Mechirova, V., Pella, D., and Fedacko, J. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol. 2007;62(4):349-354. View abstract.
  • Kumar, R., Gautam, G., and Gupta, N. P. Drug therapy for idiopathic male infertility: rationale versus evidence. J Urol. 2006;176(4 Pt 1):1307-1312. View abstract.
  • La, Vignera S., Condorelli, R., Vicari, E., D'Agata, R., and Calogero, A. E. Endothelial antioxidant compound prolonged the endothelial antiapoptotic effects registered after tadalafil treatment in patients with arterial erectile dysfunction. J Androl 2012;33(2):170-175. View abstract.
  • Labonia, W. D. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995;26(5):757-764. View abstract.
  • Lacour, B., Di Giulio, S., Chanard, J., Ciancioni, C., Haguet, M., Lebkiri, B., Basile, C., Drueke, T., Assan, R., and Funck-Brentano, J. L. Carnitine improves lipid anomalies in haemodialysis patients. Lancet 10-11-1980;2(8198):763-764. View abstract.
  • Laforet, P. and Vianey-Saban, C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul.Disord. 2010;20(11):693-700. View abstract.
  • Lagioia, R., Scrutinio, D., Mangini, S. G., Ricci, A., Mastropasqua, F., Valentini, G., Ramunni, G., Totaro, Fila G., and Rizzon, P. Propionil-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol 1992;34(2):167-172. View abstract.
  • Lango, R., Smolenski, R. T., Rogowski, J., Siebert, J., Wujtewicz, M., Slominska, E. M., Lysiak-Szydlowska, W., and Yacoub, M. H. Propionyl-L-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. Cardiovasc.Drugs Ther 2005;19(4):267-275. View abstract.
  • Larsson, L. E., Olegard, R., Ljung, B. M., Niklasson, A., Rubensson, A., and Cederblad, G. Parenteral nutrition in preterm neonates with and without carnitine supplementation. Acta Anaesthesiol.Scand. 1990;34(6):501-505. View abstract.
  • Le Tourneau, C., Faivre, S., Ciruelos, E., Dominguez, M. J., Lopez-Martin, J. A., Izquierdo, M. A., Jimeno, J., and Raymond, E. Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma. Am.J Clin Oncol. 2010;33(2):132-136. View abstract.
  • Lee, M. S., Lee, H. J., Lee, H. S., and Kim, Y. L-carnitine stimulates lipolysis via induction of the lipolytic gene expression and suppression of the adipogenic gene expression in 3T3-L1 adipocytes. J Med.Food 2006;9(4):468-473. View abstract.
  • Lee, N. C., Tang, N. L., Chien, Y. H., Chen, C. A., Lin, S. J., Chiu, P. C., Huang, A. C., and Hwu, W. L. Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. Mol.Genet.Metab 2010;100(1):46-50. View abstract.
  • Lee, P. J., Harrison, E. L., Jones, M. G., Jones, S., Leonard, J. V., and Chalmers, R. A. L-carnitine and exercise tolerance in medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency: a pilot study. J Inherit.Metab Dis. 2005;28(2):141-152. View abstract.
  • Lenzi, A., Lombardo, F., Sgro, P., Salacone, P., Caponecchia, L., Dondero, F., and Gandini, L. Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial. Fertil.Steril. 2003;79(2):292-300. View abstract.
  • Li, B., Lloyd, M. L., Gudjonsson, H., Shug, A. L., and Olsen, W. A. The effect of enteral carnitine administration in humans. Am J Clin Nutr 1992;55(4):838-845. View abstract.
  • Li, Z., Chen, G. W., Shang, X. J., Bai, W. J., Han, Y. F., Chen, B., Teng, X. M., Meng, F. H., Zhang, B., Chen, D. N., Liu, J. H., Zheng, X. M., Cao, X. R., Liu, Y., Zhu, X. B., and Wang, Y. X. A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Nat.J.Andro.(Chinese) 2005;11:761-764.
  • Li, Z., Gu, R. H., Liu, Y., Xiang, Z. Q., Cao, X. R., Han, Y. F., Zhang, X. S., and Wang, Y. X. Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic J.Shanghai Second Med.Univ. 2005;25:292-294.
  • Liammongkolkul, S., Kuptanon, C., Wasant, P., Vatanavicharn, N., Sawangareetrakul, P., Keeratichamroen, S., Cairns, J. R. K., Srisomsap, C., and Svasti, J. Novel mutation of methylmalonyl-CoA mutase gene in a Thai infant with methylmalonic acidemia (mut0). Siriraj Med.J. 2009;61(4):215-217.
  • Liang, W. C., Ohkuma, A., Hayashi, Y. K., Lopez, L. C., Hirano, M., Nonaka, I., Noguchi, S., Chen, L. H., Jong, Y. J., and Nishino, I. ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscul.Disord. 2009;19(3):212-216. View abstract.
  • Lim, C. Y., Jun, D. W., Jang, S. S., Cho, W. K., Chae, J. D., and Jun, J. H. Effects of carnitine on peripheral blood mitochondrial DNA copy number and liver function in non-alcoholic fatty liver disease. Korean J Gastroenterol. 2010;55(6):384-389. View abstract.
  • Liu, S., Wu, H. J., Zhang, Z. Q., Chen, Q., Liu, B., Wu, J. P., and Zhu, L. L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase. Cancer Biol.Ther 7-15-2011;12(2):125-130. View abstract.
  • Loffredo, L., Marcoccia, A., Pignatelli, P., Andreozzi, P., Borgia, M. C., Cangemi, R., Chiarotti, F., and Violi, F. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur.Heart J 2007;28(5):608-612. View abstract.
  • Loffredo, L., Pignatelli, P., Cangemi, R., Andreozzi, P., Panico, M. A., Meloni, V., and Violi, F. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. J Vasc.Surg. 2006;44(3):525-530. View abstract.
  • Loumbakis P, Anezinis P, Evangeliou A, and et al. Effect of L-carnitine in patients with asthenospermia. Eur J Urol 1996;30(Suppl 2):954.
  • Lu, S. M., Li, X., Zhang, H. B., Hu, J. M., Yan, J. H., Liu, J. L., and Chen, Z. J. [Use of L-carnitine before percutaneous epididymal sperm aspiration-intracytoplasmic sperm injection for obstructive azoospermia]. Zhonghua Nan.Ke.Xue. 2010;16(10):919-921. View abstract.
  • Lund, A. M., Joensen, F., Hougaard, D. M., Jensen, L. K., Christensen, E., Christensen, M., Norgaard-Petersen, B., Schwartz, M., and Skovby, F. Carnitine transporter and holocarboxylase synthetase deficiencies in The Faroe Islands. J Inherit.Metab Dis 2007;30(3):341-349. View abstract.
  • Lynch, K. E., Feldman, H. I., Berlin, J. A., Flory, J., Rowan, C. G., and Brunelli, S. M. Effects of L-carnitine on dialysis-related hypotension and muscle cramps: a meta-analysis. Am.J Kidney Dis 2008;52(5):962-971. View abstract.
  • Ma, S. J., Cai, W. W., and Sheng, J. The effects of anti-anxiety and depression therapy on life quality of patient with coronary heart disease. Chinese J.Clin.Healthcare 2008;11(5):478-480.
  • Ma, Y. Y., Song, J. Q., Wu, T. F., Liu, Y. P., Xiao, J. X., Jiang, Y. W., and Yang, Y. L. [Leucodystrophy induced by late onset 3-hydroxy-3-methylglutaric aciduria]. Zhongguo Dang.Dai Er.Ke.Za Zhi. 2011;13(5):392-395. View abstract.
  • Maccio, A., Madeddu, C., Gramignano, G., Mulas, C., Floris, C., Sanna, E., Cau, M. C., Panzone, F., and Mantovani, G. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol.Oncol 2012;124(3):417-425. View abstract.
  • Madeddu, C., Dessi, M., Panzone, F., Serpe, R., Antoni, G., Cau, M. C., Montaldo, L., Mela, Q., Mura, M., Astara, G., Tanca, F. M., Maccio, A., and Mantovani, G. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib +/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 2012;31(2):176-182. View abstract.
  • Maebashi, M., Kawamura, N., Sato, M., Imamura, A., and Yoshinaga, K. Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia. Lancet 10-14-1978;2(8094):805-807. View abstract.
  • Maestri, A., De Pasquale, Ceratti A., Cundari, S., Zanna, C., Cortesi, E., and Crino, L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005;91(2):135-138. View abstract.
  • Maggi GC, Lomanto B, and Mazzola, C. Double-blind multicenter clinical trial on the efficacy of phosphocreatinine vs L-carnitine and placebo in a group of patients affected by heart disease. Acta Toxicol Ther 1990;11(2):173-184.
  • Maillart, E., Acquaviva-Bourdain, C., Rigal, O., Brivet, M., Jardel, C., Lombes, A., Eymard, B., Vianey-Saban, C., and Laforet, P. [Multiple acyl-CoA dehydrogenase deficiency (MADD): a curable cause of genetic muscular lipidosis]. Rev.Neurol.(Paris) 2010;166(3):289-294. View abstract.
  • Malaguarnera, M., Bella, R., Vacante, M., Giordano, M., Malaguarnera, G., Gargante, M. P., Motta, M., Mistretta, A., Rampello, L., and Pennisi, G. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand.J Gastroenterol. 2011;46(6):750-759. View abstract.
  • Malaguarnera, M., Gargante, M. P., Cristaldi, E., Colonna, V., Messano, M., Koverech, A., Neri, S., Vacante, M., Cammalleri, L., and Motta, M. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Arch.Gerontol.Geriatr. 2008;46(2):181-190. View abstract.
  • Malaguarnera, M., Gargante, M. P., Cristaldi, E., Vacante, M., Risino, C., Cammalleri, L., Pennisi, G., and Rampello, L. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig.Dis Sci 2008;53(11):3018-3025. View abstract.
  • Malaguarnera, M., Gargante, M. P., Russo, C., Antic, T., Vacante, M., Malaguarnera, M., Avitabile, T., Li, Volti G., and Galvano, F. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial. Am.J Gastroenterol. 2010;105(6):1338-1345. View abstract.
  • Malaguarnera, M., Pistone, G., Astuto, M., Dell'Arte, S., Finocchiaro, G., Lo, Giudice E., and Pennisi, G. L-Carnitine in the treatment of mild or moderate hepatic encephalopathy. Dig.Dis. 2003;21(3):271-275. View abstract.
  • Malaguarnera, M., Pistone, G., Astuto, M., Vecchio, I., Raffaele, R., Lo, Giudice E., and Rampello, L. Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig.Dis Sci 2006;51(12):2242-2247. View abstract.
  • Malaguarnera, M., Pistone, G., Elvira, R., Leotta, C., Scarpello, L., and Liborio, R. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol. 12-7-2005;11(45):7197-7202. View abstract.
  • Malaguarnera, M., Risino, C., Cammalleri, L., Malaguarnera, L., Astuto, M., Vecchio, I., and Rampello, L. Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. Eur.J Gastroenterol.Hepatol. 2009;21(7):762-770. View abstract.
  • Malaguarnera, M., Vacante, M., Avitabile, T., Malaguarnera, M., Cammalleri, L., and Motta, M. L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin.Nutr 2009;89(1):71-76. View abstract.
  • Malaguarnera, M., Vacante, M., Bertino, G., Neri, S., Malaguarnera, M., Gargante, M. P., Motta, M., Lupo, L., Chisari, G., Bruno, C. M., Pennisi, G., and Bella, R. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-alpha 2b plus ribavirin. J Interferon Cytokine Res 2011;31(9):653-659. View abstract.
  • Malaguarnera, M., Vacante, M., Giordano, M., Motta, M., Bertino, G., Pennisi, M., Neri, S., Malaguarnera, M., Li, Volti G., and Galvano, F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-alpha 2b plus ribavirin. World J Gastroenterol. 10-21-2011;17(39):4414-4420. View abstract.
  • Malaguarnera, M., Vacante, M., Giordano, M., Pennisi, G., Bella, R., Rampello, L., Malaguarnera, M., Li, Volti G., and Galvano, F. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Am.J Clin Nutr. 2011;93(4):799-808. View abstract.
  • Malaguarnera, M., Vacante, M., Motta, M., Giordano, M., Malaguarnera, G., Bella, R., Nunnari, G., Rampello, L., and Pennisi, G. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis 2011;26(4):281-289. View abstract.
  • Malaguarnera, M., Vacante, M., Motta, M., Malaguarnera, M., Li, Volti G., and Galvano, F. Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism 2009;58(11):1618-1623. View abstract.
  • Malone, M. A., Schocken, D. D., Hanna, S. K., Liang, X., and Malone, J. I. Diabetes-induced bradycardia is an intrinsic metabolic defect reversed by carnitine. Metabolism 2007;56(8):1118-1123. View abstract.
  • Malvagia, S., Papi, L., Morrone, A., Donati, M. A., Ciani, F., Pasquini, E., la, Marca G., Scholte, H. R., Genuardi, M., and Zammarchi, E. Fatal malonyl CoA decarboxylase deficiency due to maternal uniparental isodisomy of the telomeric end of chromosome 16. Ann.Hum.Genet. 2007;71(Pt 6):705-712. View abstract.
  • Mantero MA, Barbero M, Giannini R, and et al. Acetyl-L-carnitine as a therapeutic agent for mental deterioration in geriatric patients (Double-blind placebo controlled study). New Trends Clin Neuropharmacol 1989;3(1):17-24.
  • Mantovani, G. Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. Eur.Rev.Med.Pharmacol Sci 2010;14(4):292-301. View abstract.
  • Mantovani, G., Maccio, A., Madeddu, C., Gramignano, G., Serpe, R., Massa, E., Dessi, M., Tanca, F. M., Sanna, E., Deiana, L., Panzone, F., Contu, P., and Floris, C. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 2008;24(4):305-313. View abstract.
  • Mantovani, G., Maccio, A., Madeddu, C., Serpe, R., Massa, E., Dessi, M., Panzone, F., and Contu, P. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15(2):200-211. View abstract.
  • Marti-Carvajal, A. J., Knight-Madden, J. M., and Martinez-Zapata, M. J. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane.Database.Syst.Rev. 2012;11:CD008394. View abstract.
  • Martina, B., Zuber, M., Weiss, P., Burkart, F., and Ritz, R. [Anti-arrhythmia treatment using L-carnitine in acute myocardial infarct]. Schweiz.Med Wochenschr 9-12-1992;122(37):1352-1355. View abstract.
  • Martinotti, G., Andreoli, S., Reina, D., Di, Nicola M., Ortolani, I., Tedeschi, D., Fanella, F., Pozzi, G., Iannoni, E., D'Iddio, S., and Prof, L. J. Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Prog.Neuropsychopharmacol.Biol.Psychiatry 6-1-2011;35(4):953-958. View abstract.
  • Martinotti, G., Reina, D., Di, Nicola M., Andreoli, S., Tedeschi, D., Ortolani, I., Pozzi, G., Iannoni, E., D'Iddio, S., and Janiri, L. Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial. Alcohol Alcohol 2010;45(5):449-455. View abstract.
  • Mate, A., Miguel-Carrasco, J. L., Monserrat, M. T., and Vazquez, C. M. Systemic antioxidant properties of L-carnitine in two different models of arterial hypertension. J Physiol Biochem. 2010;66(2):127-136. View abstract.
  • McMackin, C. J., Widlansky, M. E., Hamburg, N. M., Huang, A. L., Weller, S., Holbrook, M., Gokce, N., Hagen, T. M., Keaney, J. F., Jr., and Vita, J. A. Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens.(Greenwich.) 2007;9(4):249-255. View abstract.
  • Megri K, Trombert JC Zannier A. Effect de la L-carnitine chez les patients en hemodialyse chronique traite e par erythropoietine recombinante [abstract]. Nephrologie 1998;19:171.
  • Melegh, B., Kerner, J., Sandor, A., Vinceller, M., and Kispal, G. Effects of oral L-carnitine supplementation in low-birth-weight premature infants maintained on human milk. Biol.Neonate 1987;51(4):185-193. View abstract.
  • Mercadal, L., Coudert, M., Vassault, A., Pieroni, L., Debure, A., Ouziala, M., Depreneuf, H., Fumeron, C., Servais, A., Bassilios, N., Becart, J., Assogba, U., Allouache, M., Bouali, B., Luong, N., Dousseaux, M. P., Tezenas-du, Montcel S., and Deray, G. L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol. 2012;7(11):1836-1842. View abstract.
  • Merchant, R., Jain, A., Udani, A., Puri, V., and Kotian, M. L-carnitine in beta thalassemia. Indian Pediatr. 2010;47(2):165-167. View abstract.
  • Mettang, T., Thomas, S., and Kuhlmann, U. L-carnitine does not alleviate uremic pruritus in hemodialysis patients. Nephron 1997;75(3):372. View abstract.
  • Miguel-Carrasco, J. L., Mate, A., Monserrat, M. T., Arias, J. L., Aramburu, O., and Vazquez, C. M. The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am.J Hypertens. 2008;21(11):1231-1237. View abstract.
  • Mikhailova, T. L., Sishkova, E., Poniewierka, E., Zhidkov, K. P., Bakulin, I. G., Kupcinskas, L., Lesniakowski, K., Grinevich, V. B., Malecka-Panas, E., Ardizzone, S., D'Arienzo, A., Valpiani, D., Koch, M., Denapiene, G., Vago, G., Fociani, P., Zerbi, P., Ceracchi, M., Camerini, R., and Gasbarrini, G. Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Aliment.Pharmacol Ther 2011;34(9):1088-1097. View abstract.
  • Milazzo, L., Menzaghi, B., Caramma, I., Nasi, M., Sangaletti, O., Cesari, M., Zanone, Poma B., Cossarizza, A., Antinori, S., and Galli, M. Effect of antioxidants on mitochondrial function in HIV-1-related lipoatrophy: a pilot study. AIDS Res.Hum.Retroviruses 2010;26(11):1207-1214. View abstract.
  • Miles, C. L., Candy, B., Jones, L., Williams, R., Tookman, A., and King, M. Interventions for sexual dysfunction following treatments for cancer. Cochrane.Database.Syst.Rev. 2007;(4):CD005540. View abstract.
  • Milio, G., Novo, G., Genova, C., Luigi, Almasio P., Novo, S., and Pinto, A. Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. Cardiovasc.Drugs Ther 2009;23(4):301-306. View abstract.
  • Mioli V, Tarchini R, Boggi R, and et al. Use of D,L- and L-carnitine in uraemic patients on intermittent haemodialysis. Int J Clin Pharm Res 1982;2(2):143-148.
  • Mitwalli A, Wakeel J Alam A Tarif N Abu-Afsha A. The effect of L-carnitine supplement on dialysis patients [abstract]. 1999;
  • Mitwalli, A. H., Al-Wakeel, J. S., Alam, A., Tarif, N., Abu-Aisha, H., Rashed, M., and Al, Nahed N. L-carnitine supplementation in hemodialysis patients. Saudi.J Kidney Dis Transpl. 2005;16(1):17-22. View abstract.
  • Miwa, S. and Takikawa, O. [Chronic fatigue syndrome and neurotransmitters]. Nihon Rinsho 2007;65(6):1005-1010. View abstract.
  • Molfino, A., Cascino, A., Conte, C., Ramaccini, C., Rossi, Fanelli F., and Laviano, A. Caloric restriction and L-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism. JPEN J Parenter.Enteral Nutr. 2010;34(3):295-299. View abstract.
  • Molyneux, R., Seymour, A. M., and Bhandari, S. Value of carnitine therapy in kidney dialysis patients and effects on cardiac function from human and animal studies. Curr Drug Targets. 2012;13(2):285-293. View abstract.
  • Mondillo, S., Faglia, S., D'Aprile, N., Mangiacotti, L., Campolo, M. A., Agricola, E., and Palazzuoli, V. [Therapy of arrhythmia induced by myocardial ischemia. Association of L- carnitine, propafenone and mexiletine]. Clin Ter. 1995;146(12):769-774. View abstract.
  • Moradi, M., Moradi, A., Alemi, M., Ahmadnia, H., Abdi, H., Ahmadi, A., and Bazargan-Hejazi, S. Safety and efficacy of clomiphene citrate and L-carnitine in idiopathic male infertility: a comparative study. Urol.J 2010;7(3):188-193. View abstract.
  • Morano, S., Mandosi, E., Fallarino, M., Gatti, A., Tiberti, C., Sensi, M., Gandini, L., Buchetti, B., Lenti, L., Jannini, E. A., and Lenzi, A. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur.Urol. 2007;52(6):1768-1774. View abstract.
  • Morgante, G., Scolaro, V., Tosti, C., Di, Sabatino A., Piomboni, P., and De, Leo, V. [Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia]. Minerva Urol.Nefrol. 2010;62(3):213-218. View abstract.
  • Moustafa, A. M. and Boshra, V. The possible role of L-carnitine on the skeletal muscle of ovariectomized rats. J Mol.Histol. 2011;42(3):217-225. View abstract.
  • Muniyappa, R. Oral carnitine therapy and insulin resistance. Hypertension 2010;55(2):e13. View abstract.
  • Musso, G., Gambino, R., Cassader, M., and Pagano, G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52(1):79-104. View abstract.
  • Nagai, N., Kameda, N., Kobashi, R., Nishida, M., Horikawa, C., Egawa, K., Yoshimura, M., Kitagawa, Y., Abe, K., Kiso, Y., Sakane, N., Kotani, K., and Moritani, T. Effect of L-carnitine intake upon reduction of hunger feeling in young healthy females. J.Japanese Society Nutrition Food Sci 2007;60(5):257-264.
  • Nasca D, Zurria G, and Aguglia E. Action of acetyl-L-carnitine in association with mianserine on depressed old people. New Trends Clin Neuropharmacol 1989;3(4):225-230.
  • Nasser, M., Javaheri, H., Fedorowicz, Z., and Noorani, Z. Carnitine supplementation for inborn errors of metabolism. Cochrane.Database.Syst.Rev. 2009;(2):CD006659. View abstract.
  • Nasser, M., Javaheri, H., Fedorowicz, Z., and Noorani, Z. Carnitine supplementation for inborn errors of metabolism. Cochrane.Database.Syst.Rev. 2012;2:CD006659. View abstract.
  • Nikolaos, S., George, A., Telemachos, T., Maria, S., Yannis, M., and Konstantinos, M. Effect of L-carnitine supplementation on red blood cells deformability in hemodialysis patients. Ren Fail. 2000;22(1):73-80. View abstract.
  • Nilsson-Ehle, P., Cederblad, G., Fagher, B., Monti, M., and Thysell, H. Plasma lipoproteins, liver function and glucose metabolism in haemodialysis patients: lack of effect of L-carnitine supplementation. Scand.J Clin Lab Invest 1985;45(2):179-184. View abstract.
  • Nourshahi, M., Kaviani, M., Kimiagar, M., and Ebrahim, K. H. The effects of acute L-carnitine supplementation on anaerobic threshold and lactate accumulation during an incremental exercise. Iranian J.Nutr.Sci.Food Technol. 2009;4(27):45-52.
  • Nourshahi, M., Rajaeyan, A., Kimiagar, M., and Ebrahim, K. The effects of L-carnitine supplementation in different phases of menstrual cycle on the metabolic responses after exhausted exercise in active women. Iranian J.Nutr.Sci.Food Technol. 2011;6(1):23-32.
  • Novak M, Monkus EF, Buch M, and et al. L-carnitine supplementation of a soybean-based formula in early infancy: plasma and urine levels of carnitine and acylcarnitines. J Pediatr Gastroenterol Nutr 1987;7:220-224.
  • O'Brien, D., Chunduri, P., Iyer, A., and Brown, L. L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats. Basic Clin Pharmacol Toxicol. 2010;106(4):296-301. View abstract.
  • O'Donnell, J., Finer, N. N., Rich, W., Barshop, B. A., and Barrington, K. J. Role of L-carnitine in apnea of prematurity: a randomized, controlled trial. Pediatrics 2002;109(4):622-626. View abstract.
  • Orlandi, A., Francesconi, A., Ferlosio, A., Di, Lascio A., Marcellini, M., Pisano, C., and Spagnoli, L. G. Propionyl-L-carnitine prevents age-related myocardial remodeling in the rabbit. J Cardiovasc.Pharmacol 2007;50(2):168-175. View abstract.
  • Orlando G and Rusconi C. Oral L-carnitine in the treatment of chronic cardiac ischaemia in elderly patients. Clinical Trials Journal 1986;23(6):338-344.
  • Pacheco, A., Torres, R., Sanhueza, M. E., Elgueta, L., Segovia, E., and Cano, M. [Study of aerobic capacity in chronic hemodialized patients: effect of L-carnitine supplementation]. Med.Clin (Barc.) 4-5-2008;130(12):441-445. View abstract.
  • Palazzuoli, V., Mondillo, S., Faglia, S., D'Aprile, N., Camporeale, A., and Gennari, C. [The evaluation of the antiarrhythmic activity of L-carnitine and propafenone in ischemic cardiopathy]. Clin Ter. 1993;142(2):155-159. View abstract.
  • Pande, S., Brion, L. P., Campbell, D. E., Gayle, Y., and Esteban-Cruciani, N. V. Lack of effect of L-carnitine supplementation on weight gain in very preterm infants. J Perinatol. 2005;25(7):470-477. View abstract.
  • Panjwani, U., Thakur, L., Anand, J. P., Singh, S. N., Amitabh, Singh, S. B., and Banerjee, P. K. Effect of L-carnitine supplementation on endurance exercise in normobaric/normoxic and hypobaric/hypoxic conditions. Wilderness.Environ.Med. 2007;18(3):169-176. View abstract.
  • Park, H. D., Kim, S. R., Ki, C. S., Lee, S. Y., Chang, Y. S., Jin, D. K., and Park, W. S. Two novel HADHB gene mutations in a Korean patient with mitochondrial trifunctional protein deficiency. Ann.Clin Lab Sci 2009;39(4):399-404. View abstract.
  • Passeri, M., Iannuccelli, M., Ciotti, G., Bonati, P. A., Nolfe, G., and Cucinotta, D. Mental impairment in aging: selection of patients, methods of evaluation and therapeutic possibilities of acetyl-L-carnitine. Int J Clin Pharmacol Res 1988;8(5):367-376. View abstract.
  • Pastoris, O., Dossena, M., Foppa, P., Catapano, M., Arbustini, E., Bellini, O., Dal Bello, B., Minzioni, G., Ceriana, P., and Barzaghi, N. Effect of L-carnitine on myocardial metabolism: results of a balanced, placebo-controlled, double-blind study in patients undergoing open heart surgery. Pharmacol Res 1998;37(2):115-122. View abstract.
  • Patrikarea A, Stamatelow K Ntaountaki I Papadakis IT. The effect of combined L-carnitine and erythropoietin administration on the anaemia and on the lipid profile of patients on hemodialysis [abstract]. Nephrol Dial Transplant 1996;11:A262.
  • Payne, C., Wiffen, P. J., and Martin, S. Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane.Database.Syst.Rev. 2012;1:CD008427. View abstract.
  • Pehlivanoglu S, Enar R Mutlu H Sert A Ersalni M Yazicioglu N. The effect of L-carnitine on left ventricular function in patients with acute myocardial infarction treated with streptokinase. Türk Kardiyol Dern Ars ¸-Arch Turk Soc Cardiol. 1996;24(4):251-255.
  • Peivandi, S., Karimpour, A., and Moslemizadeh, N. Effects of L-carnitine on infertile men's spermogram; a randomized clinical trial. J.Reprod.Infertil 2010;10(4):245-251.
  • Penn, D., Schmidt-Sommerfeld, E., and Pascu, F. Decreased tissue carnitine concentrations in newborn infants receiving total parenteral nutrition. J Pediatr 1981;98(6):976-978. View abstract.
  • Penn, D., Schmidt-Sommerfeld, E., and Wolf, H. Carnitine deficiency in premature infants receiving total parenteral nutrition. Early Hum.Dev. 1980;4(1):23-34. View abstract.
  • Perez-Oliva, J. F., Guillen, Y., Gutierrez, F., and Parodis, Y. [Reduction of hospitalization thanks to L-carnitine in hemodialyzed patients]. Nefrologia. 2006;26(4):499-500. View abstract.
  • Perna, A. F., Acanfora, F., Satta, E., Lombardi, C., Capasso, R., Ingrosso, D., and De Santo, N. G. L-Propionyl carnitine, homocysteine and S-adenosylhomocysteine in hemodialysis. J Nephrol. 2007;20(1):63-65. View abstract.
  • Perrott, J., Murphy, N. G., and Zed, P. J. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann.Pharmacother. 2010;44(7-8):1287-1293. View abstract.
  • Pesce, V., Fracasso, F., Cassano, P., Lezza, A. M., Cantatore, P., and Gadaleta, M. N. Acetyl-L-carnitine supplementation to old rats partially reverts the age-related mitochondrial decay of soleus muscle by activating peroxisome proliferator-activated receptor gamma coactivator-1alpha-dependent mitochondrial biogenesis. Rejuvenation.Res. 2010;13(2-3):148-151. View abstract.
  • Pettegrew, J. W., Levine, J., Gershon, S., Stanley, J. A., Servan-Schreiber, D., Panchalingam, K., and McClure, R. J. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar.Disord. 2002;4(1):61-66. View abstract.
  • Phillips, T. J., Cherry, C. L., Cox, S., Marshall, S. J., and Rice, A. S. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS.One. 2010;5(12):e14433. View abstract.
  • Pichard, C., Roulet, M., Rossle, C., Chiolero, R., Schutz, Y., Temler, E., Boumghar, M., Schindler, C., Zurlo, F., Jequier, E., and . Effects of L-carnitine supplemented total parenteral nutrition on lipid and energy metabolism in postoperative stress. JPEN J Parenter.Enteral Nutr 1988;12(6):555-562. View abstract.
  • Pichard, C., Roulet, M., Schutz, Y., Rossle, C., Chiolero, R., Temler, E., Schindler, C., Zurlo, F., Furst, P., and Jequier, E. Clinical relevance of L-carnitine-supplemented total parenteral nutrition in postoperative trauma. Metabolic effects of continuous or acute carnitine administration with special reference to fat oxidation and nitrogen utilization. Am J Clin Nutr 1989;49(2):283-289. View abstract.
  • Pickard, R. Editorial comment on: Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur.Urol. 2007;52(6):1774-1775. View abstract.
  • Pietropaoli, P., Caporelli, S., De Pace, F., Donati, A., Adrario, E., Luzi, A., Munch, C., Giovannini, C., and Frezzotti, A. R. [Intraoperative lactic acidosis, can it be treated? Clinico- experimental, prospective, sequential study]. Minerva Anestesiol. 1994;60(12):707-713. View abstract.
  • Pignatelli, P., Tellan, G., Marandola, M., Carnevale, R., Loffredo, L., Schillizzi, M., Proietti, M., Violi, F., Chirletti, P., and Delogu, G. Effect of L-carnitine on oxidative stress and platelet activation after major surgery. Acta Anaesthesiol.Scand. 2011;55(8):1022-1028. View abstract.
  • Pittler, M. H. and Ernst, E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin J Pain 2008;24(8):731-733. View abstract.
  • Plochl, E., Sperl, W., Wermuth, B., and Colombo, J. P. [Carnitine deficiency and carnitine therapy in a patient with Rett syndrome]. Klin Padiatr. 1996;208(3):129-134. View abstract.
  • Pola P, Savi M, Grilli M, and et al. Carnitine in the therapy of dyslipidemic patients. Curr Ther Res 1980;27(2):208-216.
  • Pola P, Tondi P, Dal Lago A, and et al. Statistical evaluation of long-term L-carnitine therapy in hyperlipoproteinaemias. Drugs Exper Clin Res 1983;9:925-934.
  • Pola, P., Tondi, P., Flore, R., Serricchio, M., Dal Lago, A., Amanti, C., Consorti, F., Benedetti, M., and Midiri, H. Effect of l-carnitine on lipid pattern in debilitated patients treated with Intralipid. Int J Clin Pharmacol Res 1983;3(3):179-184. View abstract.
  • Pollard, L. M., Williams, N. R., Espinoza, L., Wood, T. C., Spector, E. B., Schroer, R. J., and Holden, K. R. Diagnosis, treatment, and long-term outcomes of late-onset (type III) multiple acyl-CoA dehydrogenase deficiency. J Child Neurol. 2010;25(8):954-960. View abstract.
  • Porter, N. S., Jason, L. A., Boulton, A., Bothne, N., and Coleman, B. Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. J.Altern.Complement Med. 2010;16(3):235-249. View abstract.
  • Pryor, J. L., Glass, S. L., Campagnone, J., and Sigman, M. Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertil.Steril 2003;80(Suppl 3):48.
  • Pucciarelli, G., Mastursi, M., Latte, S., Sacra, C., Setaro, A., Lizzadro, A., and Nolfe, G. [The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure]. Clin Ter. 1992;141(11):379-384. View abstract.
  • Pueschel, S. M. The effect of acetyl-L-carnitine administration on persons with Down syndrome. Res.Dev.Disabil. 2006;27(6):599-604. View abstract.
  • Pugliese, D., Sabba, C., Ettorre, G., Berardi, E., Antonica, G., Godi, L., Palasciano, G., Lee, S. S., and Albano, O. Acute systemic and splanchnic haemodynamic effects of L-carnitine in patients with cirrhosis. Drugs Exp Clin Res 1992;18(4):147-153. View abstract.
  • Quatraro, A., Roca, P., Donzella, C., Acampora, R., Marfella, R., and Giugliano, D. Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologia 1995;38(1):123. View abstract.
  • Rahbar, A. R., Shakerhosseini, R., Saadat, N., Taleban, F., Pordal, A., and Gollestan, B. Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus. Eur.J Clin.Nutr. 2005;59(4):592-596. View abstract.
  • Rajasekar, P. and Anuradha, C. V. Effect of L-carnitine on skeletal muscle lipids and oxidative stress in rats fed high-fructose diet. Exp.Diabetes Res. 2007;2007:72741. View abstract.
  • Rajasekar, P. and Anuradha, C. V. L-Carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management. Acta Diabetol. 2007;44(2):83-90. View abstract.
  • Rajasekar, P., Palanisamy, N., and Anuradha, C. V. Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by L-carnitine: a study in the fructose-fed hypertensive rat. Clin Exp.Hypertens. 2007;29(8):517-530. View abstract.
  • Rathod, R., Baig, M. S., Khandelwal, P. N., Kulkarni, S. G., Gade, P. R., and Siddiqui, S. Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine supplementation on health-related quality of life in Indian patients on maintenance hemodialysis. Indian J Med.Sci 2006;60(4):143-153. View abstract.
  • Rebuzzi AG, Schiavani G, Amico C, and et al. Beneficial effects of L-carnitine in the reduction of the necrotic area in acute myocardial infarction. Drugs Exp Clin Res 1984;10(4):219-223.
  • Remington, R., Chan, A., Paskavitz, J., and Shea, T. B. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am.J Alzheimers.Dis Other Demen. 2009;24(1):27-33. View abstract.
  • Reuter, S. E. and Evans, A. M. Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity. J Intern.Med. 2011;270(1):76-84. View abstract.
  • Ribas, G. S., Manfredini, V., de Mari, J. F., Wayhs, C. Y., Vanzin, C. S., Biancini, G. B., Sitta, A., Deon, M., Wajner, M., and Vargas, C. R. Reduction of lipid and protein damage in patients with disorders of propionate metabolism under treatment: a possible protective role of L-carnitine supplementation. Int.J Dev.Neurosci. 2010;28(2):127-132. View abstract.
  • Ricci, A., Caiati, C., Galantino, A., Scrutinio, D., Valentini, G., Chiddo, A., and Rizzon, P. [Acute effects of propionyl-L-carnitine on anomalies of parietal kinetics of the left ventricle induced by atrial pacing in patients with ischemic heart disease. A bidimensional echocardiographic study]. Cardiologia 1989;34(7):651-655. View abstract.
  • Riccioni, C., Sarcinella, R., Izzo, A., Palermo, G., Liguori, M., Caliumi, C., Carloni, E., Paolucci, A. M., D'andrea, P., and Pompili, S. Rehabilitative treatment in peripheral artery disease: protocol application and follow-up. Minerva Cardioangiol. 2010;58(5):551-565. View abstract.
  • Riccioni, C., Sarcinella, R., Palermo, G., Izzo, A., Liguori, M., Koverech, A., Messano, M., and Virmani, A. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II. Int.Angiol. 2008;27(3):253-259. View abstract.
  • Rizzon, P., Biasco, G., Di Biase, M., Boscia, F., Rizzo, U., Minafra, F., Bortone, A., Siliprandi, N., Procopio, A., Bagiella, E., and . High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. Eur Heart J 1989;10(6):502-508. View abstract.
  • Rodriguez DR, endible A, Gomez N, and et al. Drug intervention program in dyslipemic children: use of L-carnitine. Revista Latina De Cardiologia - Euroamericana 1997;18(2):25-30.
  • Rogerson, M. E., Rylance, P. B., Wilson, R., De Sousa, C., Lanigan, C., Rose, P. E., Howard, J., and Parsons, V. Carnitine and weakness in haemodialysis patients. Nephrol Dial.Transplant. 1989;4(5):366-371. View abstract.
  • Romano, M., Vacante, M., Cristaldi, E., Colonna, V., Gargante, M. P., Cammalleri, L., and Malaguarnera, M. L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. Dig.Dis Sci 2008;53(4):1114-1121. View abstract.
  • Ross, C., Morriss, A., Khairy, M., Khalaf, Y., Braude, P., Coomarasamy, A., and El-Toukhy, T. A systematic review of the effect of oral antioxidants on male infertility. Reprod.Biomed.Online. 2010;20(6):711-723. View abstract.
  • Rossignol, D. A. and Frye, R. E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol.Psychiatry 2012;17(3):290-314. View abstract.
  • Rossignol, D. A. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann.Clin Psychiatry 2009;21(4):213-236. View abstract.
  • Rossini, D., Bulckaen, M., Di, Marco S., Giovannetti, R., Giuntoli, F., Lacopetti, L., and Vergoni, W. [Rehabilitation program in patients with moderate-to-severe intermittent claudication: immediate results and one year follow-up]. Monaldi Arch.Chest Dis 2007;68(2):110-114. View abstract.
  • Rossini, M., Di, Munno O., Valentini, G., Bianchi, G., Biasi, G., Cacace, E., Malesci, D., La, Montagna G., Viapiana, O., and Adami, S. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp.Rheumatol. 2007;25(2):182-188. View abstract.
  • Rossini, P. M., Marchionno, L., Gambi, D., Pirchio, M., Del Rosso, G., and Albertazzi, A. EMG changes in chronically dialyzed uraemic subjects undergoing d, 1- Carnitine treatment. Ital J Neurol Sci 1981;2(3):255-262. View abstract.
  • Rossle, C., Pichard, C., Roulet, M., Chiolero, R., Schutz, Y., Temler, E., Schindler, C., Zurlo, F., Jequier, E., and Furst, P. [Effect of L-carnitine supplemented total parenteral nutrition on postoperative lipid and nitrogen utilization]. Klin.Wochenschr 12-15-1988;66(24):1202-1211. View abstract.
  • Roure, R., Oddos, T., Rossi, A., Vial, F., and Bertin, C. Evaluation of the efficacy of a topical cosmetic slimming product combining tetrahydroxypropyl ethylenediamine, caffeine, carnitine, forskolin and retinol, In vitro, ex vivo and in vivo studies. Int.J Cosmet.Sci 2011;33(6):519-526. View abstract.
  • Roy, M. J., Dionne, S., Marx, G., Qureshi, I., Sarma, D., Levy, E., and Seidman, E. G. In vitro studies on the inhibition of colon cancer by butyrate and carnitine. Nutrition 2009;25(11-12):1193-1201. View abstract.
  • Rueda, J. R., Ballesteros, J., and Tejada, M. I. Systematic review of pharmacological treatments in fragile X syndrome. BMC.Neurol. 2009;9:53. View abstract.
  • Ruggenenti, P., Cattaneo, D., Loriga, G., Ledda, F., Motterlini, N., Gherardi, G., Orisio, S., and Remuzzi, G. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension 2009;54(3):567-574. View abstract.
  • Russell, S. Carnitine as an antidote for acute valproate toxicity in children. Curr.Opin.Pediatr. 2007;19(2):206-210. View abstract.
  • Sabba, C., Berardi, E., Antonica, G., Ferraioli, G., Buonamico, P., Godi, L., Brevetti, G., and Albano, O. Comparison between the effect of L-propionylcarnitine, L- acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study. Eur Heart J 1994;15(10):1348-1352. View abstract.
  • Sabry, A. A. The role of oral L-carnitine therapy in chronic hemodialysis patients. Saudi.J Kidney Dis Transpl. 2010;21(3):454-459. View abstract.
  • Sabry, A. A., Ghaith, O., Medhat, T., George, S. K., and Elshafey, E. M. Is there a role for oral L-carnitine therapy in anemia and cardiac dysfunction management in Egyptian patients on maintenance hemodialysis? Eur.J.Gen.Med 2009;6(2):7-15.
  • Safarinejad, M. R., Hosseini, S. Y., and Kolahi, A. A. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178(4 Pt 1):1398-1403. View abstract.
  • Sahajwalla, C. G., Helton, E. D., Purich, E. D., Hoppel, C. L., and Cabana, B. E. Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330-mg tablet versus 1-g chewable tablet versus enteral solution in healthy adult male volunteers. J Pharm Sci 1995;84(5):627-633. View abstract.
  • Sakurabayashi, T., Miyazaki, S., Yuasa, Y., Sakai, S., Suzuki, M., Takahashi, S., and Hirasawa, Y. L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ.J 2008;72(6):926-931. View abstract.
  • Sakurauchi, Y., Matsumoto, Y., Shinzato, T., Takai, I., Nakamura, Y., Sato, M., Nakai, S., Miwa, M., Morita, H., Miwa, T., Amano, I., and Maeda, K. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. Am J Kidney Dis. 1998;32(2):258-264. View abstract.
  • Salonia, A. Editorial comment on: Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur.Urol. 2007;52(6):1775-1776. View abstract.
  • Sandor, A., Pecsuvac, K., Kerner, J., and Alkonyi, I. On carnitine content of the human breast milk. Pediatr.Res 1982;16(2):89-91. View abstract.
  • Santo, S. S., Sergio, N., Luigi, D. P., Giuseppe, M., Margherita, F., Gea, O. C., Roberto, F., Gabriella, C., Giuseppe, P., and Massimiliano, A. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Res.Clin Pract. 2006;72(3):231-237. View abstract.
  • Sarafoglou, K., Tridgell, A. H., Bentler, K., Redlinger-Grosse, K., Berry, S. A., and Schimmenti, L. A. Cardiac conduction improvement in two heterozygotes for primary carnitine deficiency on L-carnitine supplementation. Clin Genet. 2010;78(2):191-194. View abstract.
  • Sarris, J., Kean, J., Schweitzer, I., and Lake, J. Complementary medicines (herbal and nutritional products) in the treatment of Attention Deficit Hyperactivity Disorder (ADHD): a systematic review of the evidence. Complement Ther Med 2011;19(4):216-227. View abstract.
  • Schiavoni, G., Lucente, M., Di Folca, A., Alessandri, N., Mongiardo, R., and Manzoli, U. [The anti-arrhythmic effect of L-carnitine in subjects with ischemic cardiopathy]. Clin Ter. 2-15-1981;96(3):263-270. View abstract.
  • Schoffski, P., Guillem, V., Garcia, M., Rivera, F., Tabernero, J., Cullell, M., Lopez-Martin, J. A., Pollard, P., Dumez, H., del Muro, X. G., and Paz-Ares, L. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar.Drugs 2009;7(1):57-70. View abstract.
  • Segura-Bruna, N., Rodriguez-Campello, A., Puente, V., and Roquer, J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol.Scand. 2006;114(1):1-7. View abstract.
  • Semeniuk, J., Shalansky, K. F., Taylor, N., Jastrzebski, J., and Cameron, E. C. Evaluation of the effect of intravenous l-carnitine on quality of life in chronic hemodialysis patients. Clin Nephrol. 2000;54(6):470-477. View abstract.
  • Seo, J. T., Kim, K. T., Moon, M. H., and Kim, W. T. The significance of microsurgical varicocelectomy in the treatment of subclinical varicocele. Fertil.Steril. 2010;93(6):1907-1910. View abstract.
  • Seong, S. H., Cho, S. C., Park, Y., and Cha, Y. S. L-carnitine-supplemented parenteral nutrition improves fat metabolism but fails to support compensatory growth in premature Korean infants. Nutr.Res. 2010;30(4):233-239. View abstract.
  • Serjeant, B. E., Harris, J., Thomas, P., and Serjeant, G. R. Propionyl-L-carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study. J Am Acad.Dermatol. 1997;37(3 Pt 1):491-493. View abstract.
  • Sethumadhavan, S. and Chinnakannu, P. Carnitine and lipoic acid alleviates protein oxidation in heart mitochondria during aging process. Biogerontology. 2006;7(2):101-109. View abstract.
  • Shakeri, A., Tabibi, H., and Hedayati, M. Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial.Int. 2010;14(4):498-504. View abstract.
  • Sharifi, A. M., Zare, B., Keshavarz, M., and Ghaderpanahi, M. Effect of short term treatment of L-carnitine on tissue ACE activity in streptozotocin-induced diabetic rats. Pathophysiology. 2009;16(1):53-56. View abstract.
  • Shi, J. Z., Zhang, S. S., Zhang, Z., Liang, Q., Shi, Y., Hua, J. L., and Sun, T. [Expressions of sperm-specific genes in carnitine-cultured testis sperm of obstructive azoospermia patients]. Zhonghua Nan.Ke.Xue. 2010;16(6):504-509. View abstract.
  • Shojaei, M., Djalali, M., Khatami, M., Siassi, F., and Eshraghian, M. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. Iran J Kidney Dis 2011;5(2):114-118. View abstract.
  • Shortland, G. J., Walter, J. H., Stroud, C., Fleming, P. J., Speidel, B. D., and Marlow, N. Randomised controlled trial of L-carnitine as a nutritional supplement in preterm infants. Arch Dis.Child Fetal Neonatal Ed 1998;78(3):F185-F188. View abstract.
  • Siami, G., Clinton, M. E., Mrak, R., Griffis, J., and Stone, W. Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 1991;57(3):306-313. View abstract.
  • Sigman, M., Glass, S., Campagnone, J., and Pryor, J. L. Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertil.Steril. 2006;85(5):1409-1414. View abstract.
  • Signorelli, S. S., Fatuzzo, P., Rapisarda, F., Neri, S., Ferrante, M., Oliveri, Conti G., Fallico, R., Di, Pino L., Pennisi, G., Celotta, G., and Anzaldi, M. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney Blood Press Res. 2006;29(2):100-107. View abstract.
  • Signorelli, S. S., Fatuzzo, P., Rapisarda, F., Neri, S., Ferrante, M., Oliveri, Conti G., Fallico, R., Di, Pino L., Pennisi, G., Celotta, G., and Massimiliano, A. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis. Drugs Aging 2006;23(3):263-270. View abstract.
  • Silverio, R., Laviano, A., Rossi, Fanelli F., and Seelaender, M. L-Carnitine induces recovery of liver lipid metabolism in cancer cachexia. Amino.Acids 2012;42(5):1783-1792. View abstract.
  • Sirtori, C. R., Calabresi, L., Ferrara, S., Pazzucconi, F., Bondioli, A., Baldassarre, D., Birreci, A., and Koverech, A. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc.Dis. 2000;10(5):247-251. View abstract.
  • Sloan, R. S., Kastan, B., Rice, S. I., Sallee, C. W., Yuenger, N. J., Smith, B., Ward, R. A., Brier, M. E., and Golper, T. A. Quality of life during and between hemodialysis treatments: role of L- carnitine supplementation. Am J Kidney Dis 1998;32(2):265-272. View abstract.
  • Smith, W. A., Fry, A. C., Tschume, L. C., and Bloomer, R. J. Effect of glycine propionyl-L-carnitine on aerobic and anaerobic exercise performance. Int.J Sport Nutr.Exerc.Metab 2008;18(1):19-36. View abstract.
  • Socha, P., Horvath, A., Vajro, P., Dziechciarz, P., Dhawan, A., and Szajewska, H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr.Gastroenterol.Nutr. 2009;48(5):587-596. View abstract.
  • Soczynska, J. K., Kennedy, S. H., Chow, C. S., Woldeyohannes, H. O., Konarski, J. Z., and McIntyre, R. S. Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? Expert.Opin.Investig.Drugs 2008;17(6):827-843. View abstract.
  • Sohn HJ, Choi GB Yoon KI. L-Carnitine in maintenance hemo- dialysis clinical, lipid and biochemical effects. Kor J Nephrol 1992;11:260-269.
  • Sood, A., Barton, D. L., Bauer, B. A., and Loprinzi, C. L. A critical review of complementary therapies for cancer-related fatigue. Integr.Cancer Ther 2007;6(1):8-13. View abstract.
  • Sotobatake I, Noda S, Hayashi H, and et al. Clinical evaluation of the effects of levocarnitine chloride (LC-80) on excercise tolerance in stable angina pectoris by the serial multistage treadmill exercise testing: a multicenter, double-blind study. Jpn J Clin Pharmacol Ther 1989;20(3):607-618.
  • Soyucen, E., Demirci, E., and Aydin, A. Outpatient treatment of propionic acidemia-associated hyperammonemia with N-carbamoyl-L-glutamate in an infant. Clin Ther 2010;32(4):710-713. View abstract.
  • Spasov, A. A., Iezhitsa, I. N., Kravchenko, M. S., Pisarev, V. B., and Snigur, G. L. Effects of L-, D-, and DL-carnitine on morphometric parameters of skeletal muscle and exercise performance of laboratory animals receiving carnitine-deficient diet. Bull.Exp.Biol.Med. 2006;142(4):458-460. View abstract.
  • Spiekerkoetter, U., Bastin, J., Gillingham, M., Morris, A., Wijburg, F., and Wilcken, B. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit.Metab Dis 2010;33(5):555-561. View abstract.
  • Spiekerkoetter, U., Lindner, M., Santer, R., Grotzke, M., Baumgartner, M. R., Boehles, H., Das, A., Haase, C., Hennermann, J. B., Karall, D., de, Klerk H., Knerr, I., Koch, H. G., Plecko, B., Roschinger, W., Schwab, K. O., Scheible, D., Wijburg, F. A., Zschocke, J., Mayatepek, E., and Wendel, U. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit.Metab Dis 2009;32(4):488-497. View abstract.
  • Spiering, B. A., Kraemer, W. J., Hatfield, D. L., Vingren, J. L., Fragala, M. S., Ho, J. Y., Thomas, G. A., Hakkinen, K., and Volek, J. S. Effects of L-carnitine L-tartrate supplementation on muscle oxygenation responses to resistance exercise. J Strength.Cond.Res. 2008;22(4):1130-1135. View abstract.
  • Spiering, B. A., Kraemer, W. J., Vingren, J. L., Hatfield, D. L., Fragala, M. S., Ho, J. Y., Maresh, C. M., Anderson, J. M., and Volek, J. S. Responses of criterion variables to different supplemental doses of L-carnitine L-tartrate. J Strength.Cond.Res. 2007;21(1):259-264. View abstract.
  • Sproule, D. M., Dyme, J., Coku, J., de, Vinck D., Rosenzweig, E., Chung, W. K., and De Vivo, D. C. Pulmonary artery hypertension in a child with MELAS due to a point mutation of the mitochondrial tRNA((Leu)) gene (m.3243A > G). J Inherit.Metab Dis 1-7-2008; View abstract.
  • Srivastava DK, Kumar S Misra AP. Reversal of haemodialysis induced hypertriacylglycerolemia by L-carnitine. Indian J Clin Biochem 1992;7:19-21.
  • Stuessi, C., Hofer, P., Meier, C., and Boutellier, U. L -Carnitine and the recovery from exhaustive endurance exercise: a randomised, double-blind, placebo-controlled trial. Eur J Appl Physiol 2005;95(5-6):431-435. View abstract.
  • Suchitra, M. M., Ashalatha, V. L., Sailaja, E., Rao, A. M., Reddy, V. S., Bitla, A. R., Sivakumar, V., and Rao, P. V. The effect of L-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients. Saudi.J Kidney Dis Transpl. 2011;22(6):1155-1159. View abstract.
  • Sugino, T., Aoyagi, S., Shirai, T., Kajimoto, Y., and Kajimoto, O. Effects of Citric Acid and l-Carnitine on Physical Fatigue. J Clin Biochem.Nutr. 2007;41(3):224-230. View abstract.
  • Sulkers, E. J., Lafeber, H. N., Degenhart, H. J., Przyrembel, H., Schlotzer, E., and Sauer, P. J. Effects of high carnitine supplementation on substrate utilization in low-birth-weight infants receiving total parenteral nutrition. Am J Clin Nutr 1990;52(5):889-894. View abstract.
  • Sum CF, Winocour PH, Agius L, and et al. Does oral L-carnitine alter plasma triglyceride levels in hypertriglyceridaemic subjects with or without non-insulin dependent diabetes mellitus? Diabetes Nutr Metab Clin Exp 1992;5(3):175-181.
  • Sun, Z. J., Yang, C. B., Wang, H., and Li, Y. [The impact of L-carnitine administration on the serum level of myocardium injury markers in patients with acute carbon monoxide poisoning]. Zhongguo Wei Zhong.Bing.Ji.Jiu.Yi Xue 2011;23(12):739-742. View abstract.
  • Sunamori M, Nakagawa T, Fujisawa S, and et al. Myocardial response to pretreatment with L-carnitine in patients with cardiac valve replacement. Vascular Surgery 1991;25(8):607-617.
  • Suzuki, Y., Narita, M., and Yamazaki, N. Effects of L-carnitine on arrhythmias during hemodialysis. Jpn Heart J 1982;23(3):349-359. View abstract.
  • Swart I, Rossouw J, Loots JM, and et al. The effect of L-carnitine supplementation on plasma carnitine levels and various performance parameters of male marathon athletes. Nutr Res 1997;17:405-414.
  • Swoboda, K. J., Scott, C. B., Crawford, T. O., Simard, L. R., Reyna, S. P., Krosschell, K. J., Acsadi, G., Elsheik, B., Schroth, M. K., D'Anjou, G., LaSalle, B., Prior, T. W., Sorenson, S. L., Maczulski, J. A., Bromberg, M. B., Chan, G. M., and Kissel, J. T. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS.One. 2010;5(8):e12140. View abstract.
  • Tabibi, H., Hakeshzadeh, F., Hedayati, M., and Malakoutian, T. Effects of l-carnitine supplement on serum amyloid A and vascular inflammation markers in hemodialysis patients: a randomized controlled trial. J Ren Nutr. 2011;21(6):485-491. View abstract.
  • Tanner, L. M., Nanto-Salonen, K., Rashed, M. S., Kotilainen, S., Aalto, M., Venetoklis, J., Niinikoski, H., Huoponen, K., and Simell, O. Carnitine deficiency and L-carnitine supplementation in lysinuric protein intolerance. Metabolism 2008;57(4):549-554. View abstract.
  • Tarantini, G., Scrutinio, D., Bruzzi, P., Boni, L., Rizzon, P., and Iliceto, S. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology 2006;106(4):215-223. View abstract.
  • Tarighat, Esfanjani A., Mahdavi, R., Ebrahimi, Mameghani M., Talebi, M., Nikniaz, Z., and Safaiyan, A. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol.Trace Elem.Res 2012;150(1-3):42-48. View abstract.
  • Tejani, A. M., Wasdell, M., Spiwak, R., Rowell, G., and Nathwani, S. Carnitine for fatigue in multiple sclerosis. Cochrane.Database.Syst.Rev. 2010;(2):CD007280. View abstract.
  • Tejani, A. M., Wasdell, M., Spiwak, R., Rowell, G., and Nathwani, S. Carnitine for fatigue in multiple sclerosis. Cochrane.Database.Syst.Rev. 2012;5:CD007280. View abstract.
  • Thomas, S., Fischer, F. P., Mettang, T., Pauli-Magnus, C., Weber, J., and Kuhlmann, U. Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: A double-blind randomized trial. Am.J Kidney Dis 1999;34(4):678-687. View abstract.
  • Thomsen, J. H., Shug, A. L., Yap, V. U., Patel, A. K., Karras, T. J., and DeFelice, S. L. Improved pacing tolerance of the ischemic human myocardium after administration of carnitine. Am J Cardiol. 1979;43(2):300-306. View abstract.
  • Tomassini, V., Pozzilli, C., Onesti, E., Pasqualetti, P., Marinelli, F., Pisani, A., and Fieschi, C. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol.Sci 3-15-2004;218(1-2):103-108. View abstract.
  • Toptas, B., Baykal, A., Yesilipek, A., Isbir, M., Kupesiz, A., Yalcin, O., and Baskurt, O. K. L-carnitine deficiency and red blood cell mechanical impairment in beta-thalassemia major. Clin Hemorheol.Microcirc. 2006;35(3):349-357. View abstract.
  • Torrioli, M. G., Vernacotola, S., Mariotti, P., Bianchi, E., Calvani, M., De Gaetano, A., Chiurazzi, P., and Neri, G. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am.J Med Genet. 12-3-1999;87(4):366-368. View abstract.
  • Torrioli, M. G., Vernacotola, S., Peruzzi, L., Tabolacci, E., Mila, M., Militerni, R., Musumeci, S., Ramos, F. J., Frontera, M., Sorge, G., Marzullo, E., Romeo, G., Vallee, L., Veneselli, E., Cocchi, E., Garbarino, E., Moscato, U., Chiurazzi, P., D'Iddio, S., Calvani, M., and Neri, G. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am.J Med.Genet.A 4-1-2008;146(7):803-812. View abstract.
  • Touati, G., Valayannopoulos, V., Mention, K., de, Lonlay P., Jouvet, P., Depondt, E., Assoun, M., Souberbielle, J. C., Rabier, D., Ogier de, Baulny H., and Saudubray, J. M. Methylmalonic and propionic acidurias: management without or with a few supplements of specific amino acid mixture. J Inherit.Metab Dis 2006;29(2-3):288-298. View abstract.
  • Trappe, S. W., Costill, D. L., Goodpaster, B., Vukovich, M. D., and Fink, W. J. The effects of L-carnitine supplementation on performance during interval swimming. Int J Sports Med 1994;15(4):181-185. View abstract.
  • Trivelli G, Vitali P Girmenia S Castelli F. Trattamento della dislipidemia dell'emodializzato con L-carnitina. Clin Eur 1983;22:405-415.
  • Trovato GM, Ginardi V, Di Marco V, and et al. Long-term l-carnitine treatment of chronic anaemia of patients with end-stage renal failure. Curr Ther Res 1982;31:1042-1048.
  • Turpeinen AK, Kuikka JT, Vanninen E, and et al. Long-term effects of acetyl-l-carnitine on myocardial sympathetic innervation in diabetic patients. Diabetologia 1997;40(1):A32.
  • Turpeinen, A. K., Kuikka, J. T., Vanninen, E., Yang, J., and Uusitupa, M. I. Long-term effect of acetyl-L-carnitine on myocardial 123I-MIBG uptake in patients with diabetes. Clin Auton.Res 2000;10(1):13-16. View abstract.
  • Uppin, M. S., Sundaram, C., Meena, A. K., Reddy, K. M., Reddy, K. K., Vanniarajan, A., and Thangaraj, K. Lipid storage myopathies with unusual clinical manifestations. Neurol.India 2008;56(3):391-393. View abstract.
  • Uzun, N., Sarikaya, S., Uluduz, D., and Aydin, A. Peripheric and automatic neuropathy in children with type 1 diabetes mellitus: the effect of L-carnitine treatment on the peripheral and autonomic nervous system. Electromyogr.Clin Neurophysiol. 2005;45(6):343-351. View abstract.
  • Vacha, G. M., Giorcelli, G., D'Iddio, S., Valentini, G., Bagiella, E., Procopio, A., di Donato, S., Ashbrook, D., and Corsi, M. L-carnitine addition to dialysis fluid. A therapeutic alternative for hemodialysis patients. Nephron 1989;51(2):237-242. View abstract.
  • Valcour, V., Yeh, T. M., Bartt, R., Clifford, D., Gerschenson, M., Evans, S. R., Cohen, B. A., Ebenezer, G. J., Hauer, P., Millar, L., Gould, M., Tran, P., Shikuma, C., Souza, S., and McArthur, J. C. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV.Med. 2009;10(2):103-110. View abstract.
  • van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev. 2008;(2):CD003917. View abstract.
  • van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev. 2011;(6):CD003917. View abstract.
  • Van Oudheusden, L. J. and Scholte, H. R. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot.Essent.Fatty Acids 2002;67(1):33-38. View abstract.
  • Vaux, E. C., Taylor, D. J., Altmann, P., Rajagopalan, B., Graham, K., Cooper, R., Bonomo, Y., and Styles, P. Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin.Pract. 2004;97(2):c41-c48. View abstract.
  • Verrina, E., Caruso, U., Calevo, M. G., Emma, F., Sorino, P., De, Palo T., Lavoratti, G., Turrini, Dertenois L., Cassanello, M., Cerone, R., and Perfumo, F. Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis. Pediatr.Nephrol. 2007;22(5):727-733. View abstract.
  • Villani, R. G., Gannon, J., Self, M., and Rich, P. A. L-Carnitine supplementation combined with aerobic training does not promote weight loss in moderately obese women. Int J Sport Nutr Exerc.Metab 2000;10(2):199-207. View abstract.
  • Vitali, G., Parente, R., and Melotti, C. Carnitine supplementation in human idiopathic asthenospermia: clinical results. Drugs Exp Clin Res 1995;21(4):157-159. View abstract.
  • Vivekanandan, S. and Nayak, S. D. Valproate-induced hyperammonemic encephalopathy enhanced by topiramate and phenobarbitone: a case report and an update. Ann.Indian Acad.Neurol. 2010;13(2):145-147. View abstract.
  • Volek, J. S., Judelson, D. A., Silvestre, R., Yamamoto, L. M., Spiering, B. A., Hatfield, D. L., Vingren, J. L., Quann, E. E., Anderson, J. M., Maresh, C. M., and Kraemer, W. J. Effects of carnitine supplementation on flow-mediated dilation and vascular inflammatory responses to a high-fat meal in healthy young adults. Am.J Cardiol. 11-15-2008;102(10):1413-1417. View abstract.
  • Wadman, R. I., Bosboom, W. M., van den Berg, L. H., Wokke, J. H., Iannaccone, S. T., and Vrancken, A. F. Drug treatment for spinal muscular atrophy types II and III. Cochrane.Database.Syst.Rev. 2011;(12):CD006282. View abstract.
  • Wadman, R. I., Bosboom, W. M., van der Pol, W. L., van den Berg, L. H., Wokke, J. H., Iannaccone, S. T., and Vrancken, A. F. Drug treatment for spinal muscular atrophy types II and III. Cochrane.Database.Syst.Rev. 2012;4:CD006282. View abstract.
  • Wadzinski, J., Franks, R., Roane, D., and Bayard, M. Valproate-associated hyperammonemic encephalopathy. J Am.Board Fam.Med. 2007;20(5):499-502. View abstract.
  • Waldner, R., Laschan, C., Lohninger, A., Gessner, M., Tuchler, H., Huemer, M., Spiegel, W., and Karlic, H. Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. J Cancer Res.Clin Oncol. 2006;132(2):121-128. View abstract.
  • Wall, B. T., Stephens, F. B., Constantin-Teodosiu, D., Marimuthu, K., Macdonald, I. A., and Greenhaff, P. L. Increasing muscle carnitine content alters muscle fuel metabolism and improves exercise performance in humans. Japanese J.Physical Fitness Sports Med. 2011;60(1):85.
  • Wang, J. and Wang, X. The effects of L-carnitine on human stamina. China Food Additives 2003;5:40-43.
  • Wang, S. B., Weng, W. C., Lee, N. C., Hwu, W. L., Fan, P. C., and Lee, W. T. Mutation of mitochondrial DNA G13513A presenting with Leigh syndrome, Wolff-Parkinson-White syndrome and cardiomyopathy. Pediatr.Neonatol. 2008;49(4):145-149. View abstract.
  • Wang, Y. X., Yang, S. W., Qu, C. B., Huo, H. X., Li, W., Li, J. D., Chang, X. L., and Cai, G. Z. [L-carnitine: safe and effective for asthenozoospermia]. Zhonghua Nan.Ke.Xue. 2010;16(5):420-422. View abstract.
  • Warady, B. A., Borum, P., Stall, C., Millspaugh, J., Taggart, E., and Lum, G. Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis. Am J Nephrol 1990;10(2):109-114. View abstract.
  • Watanabe, S., Ajisaka, R., Masuoka, T., Yamanouchi, T., Saitou, T., Toyama, M., Takeyasu, N., Sakamoto, K., and Sugishita, Y. Effects of L- and DL-carnitine on patients with impaired exercise tolerance. Jpn Heart J 1995;36(3):319-331. View abstract.
  • Weigel, C., Kiener, C., Meier, N., Schmid, P., Rauh, M., Rascher, W., and Knerr, I. Carnitine status in early-treated children, adolescents and young adults with phenylketonuria on low phenylalanine diets. Ann.Nutr.Metab 2008;53(2):91-95. View abstract.
  • Weinhandl, E. D., Rao, M., Gilbertson, D. T., Collins, A. J., and Pereira, B. J. Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients, 1998 to 2003. Am.J Kidney Dis 2007;50(5):803-812. View abstract.
  • Weschler, A., Aviram, M., Levin, M., Better, O. S., and Brook, J. G. High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis. Nephron 1984;38(2):120-124. View abstract.
  • Williams, S. F., Alvarez, J. R., Pedro, H. F., and Apuzzio, J. J. Glutaric aciduria type II and narcolepsy in pregnancy. Obstet.Gynecol. 2008;111(2 Pt 2):522-524. View abstract.
  • Wolfe, L. A., He, M., Vockley, J., Payne, N., Rhead, W., Hoppel, C., Spector, E., Gernert, K., and Gibson, K. M. Novel ETF dehydrogenase mutations in a patient with mild glutaric aciduria type II and complex II-III deficiency in liver and muscle. J Inherit.Metab Dis 11-19-2010; View abstract.
  • Wu, Z. M., Lu, X., Wang, Y. W., Sun, J., Tao, J. W., Yin, F. H., and Cheng, H. J. [Short-term medication of L-carnitine before intracytoplasmic sperm injection for infertile men with oligoasthenozoospermia]. Zhonghua Nan.Ke.Xue 2012;18(3):253-256. View abstract.
  • Wyss, V., Ganzit, G. P., and Rienzi, A. Effects of L-carnitine administration on VO2max and the aerobic- anaerobic threshold in normoxia and acute hypoxia. Eur J Appl Physiol Occup.Physiol 1990;60(1):1-6. View abstract.
  • Xie, H., Tang, S. Y., Li, H., Luo, X. H., Yuan, L. Q., Wang, D., and Liao, E. Y. L-carnitine protects against apoptosis of murine MC3T3-E1 osteoblastic cells. Amino.Acids 2008;35(2):419-423. View abstract.
  • Xie, J., Zeng, Q., and Wang, L. The protective effect of L-carnitine on ischemia-reperfusion heart. J Huazhong.Univ Sci Technolog.Med.Sci 2006;26(2):188-191. View abstract.
  • Xue, Y. Z., Wang, L. X., Liu, H. Z., Qi, X. W., Wang, X. H., and Ren, H. Z. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc.Drugs Ther 2007;21(6):445-448. View abstract.
  • Yang, L., Yin, H., Yang, R., and Huang, X. Diagnosis, treatment and outcome of glutaric aciduria type I in Zhejiang Province, China. Med.Sci Monit. 2011;17(7):H55-H59. View abstract.
  • Yderstraede, K. B., Pedersen, F. B., Dragsholt, C., Trostmann, A., Laier, E., and Larsen, H. F. The effect of L-carnitine on lipid metabolism in patients on chronic haemodialysis. Nephrol.Dial.Transplant. 1987;1(4):238-241. View abstract.
  • Ye, J., Li, C. J., and Liu, J. H. [A clinical analysis of methylmalonic acidemia in adolescents]. Zhonghua Nei Ke.Za Zhi. 2008;47(10):823-825. View abstract.
  • Yeh, Y. Y., Cooke, R. J., and Zee, P. Impairment of lipid emulsion metabolism associated with carnitine insufficiency in premature infants. J Pediatr Gastroenterol Nutr 1985;4(5):795-798. View abstract.
  • Yokoi, K., Ito, T., Maeda, Y., Nakajima, Y., Ueta, A., Nomura, T., Koyama, N., Kato, I., Suzuki, S., Kurono, Y., Sugiyama, N., and Togari, H. Acylcarnitine profiles during carnitine loading and fasting tests in a Japanese patient with medium-chain acyl-CoA dehydrogenase deficiency. Tohoku J Exp.Med. 2007;213(4):351-359. View abstract.
  • Youle, M. Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS.Drugs 2007;21 Suppl 1:25-30. View abstract.
  • Youle, M. and Osio, M. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV.Med. 2007;8(4):241-250. View abstract.
  • Young, P., Finn, B. C., Alvarez, F., Bruetman, J. E., and Trimarchi, H. [Valproate-associated hyperammonemic encephalopathy. Report of one case]. Rev.Med.Chil. 2007;135(11):1446-1449. View abstract.
  • Zanardi, R. and Smeraldi, E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur.Neuropsychopharmacol. 2006;16(4):281-287. View abstract.
  • Zhang, J. M., Gu, X. F., Shao, X. H., Song, X. Q., Han, L. S., Ye, J., Qiu, W. J., Gao, X. L., Wang, Y., and Wang, M. X. [Values of tandem mass spectrometry in etiologic diagnosis of cerebral developmental retardation]. Zhonghua Er.Ke.Za Zhi. 2007;45(12):932-936. View abstract.
  • Zhang, W., Miao, J., Zhang, G., Liu, R., Zhang, D., Wan, Q., Yu, Y., Zhao, G., and Li, Z. Muscle carnitine deficiency: adult onset lipid storage myopathy with sensory neuropathy. Neurol.Sci 2010;31(1):61-64. View abstract.
  • Zhang, X. L. and Ge, H. Clinical observations on treating ischemic cardiomyopathy using Fasudil and L-carnitine. Chinese J.Pract.Internal Med. 2011;31(5):376-377.
  • Zhang, Y., Song, J. Q., Liu, P., Yan, R., Dong, J. H., Yang, Y. L., Wang, L. F., Jiang, Y. W., Zhang, Y. H., Qin, J., and Wu, X. R. [Clinical studies on fifty-seven Chinese patients with combined methylmalonic aciduria and homocysteinemia]. Zhonghua Er.Ke.Za Zhi. 2007;45(7):513-517. View abstract.
  • Zhao, J. L., Gao, D. Z., Liu, D., He, H. H., She, Q., and Yin, Y. H. Improvement of exercise tolerance by L-carnitine in patients with cardiac syndrome X. Chin.Hosp.Pharm.J. 2010;30(17):1460-1463.
  • Zhou, X., Liu, F., and Zhai, S. Effect of L-carnitine and/or L-acetyl-carnitine in nutrition treatment for male infertility: a systematic review. Asia Pac.J Clin Nutr. 2007;16 Suppl 1:383-390. View abstract.
  • Zilleruelo, G., Novak, M., Hsia, S. L., Goldberg, R., Abitbol, C., Monkus, E., and Strauss, J. Effect of dialysate composition on the lipid response to L-carnitine supplementation. Kidney Int Suppl 1989;27:S259-S263. View abstract.
  • Zwickler, T., Lindner, M., Aydin, H. I., Baumgartner, M. R., Bodamer, O. A., Burlina, A. B., Das, A. M., DeKlerk, J. B., Gokcay, G., Grunewald, S., Guffon, N., Maier, E. M., Morava, E., Geb, S., Schwahn, B., Walter, J. H., Wendel, U., Wijburg, F. A., Muller, E., Kolker, S., and Horster, F. Diagnostic work-up and management of patients with isolated methylmalonic acidurias in European metabolic centres. J Inherit.Metab Dis 2008;31(3):361-367. View abstract.
  • 12761 Benvenga S, Amato A, Calvani M, Trimarchi F. Effects of carnitine on thyroid hormone action. Ann N Y Acad Sci 2004;1033:158-67. View abstract.
  • Ahmad S, Robertson HT, Golper TA, et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 1990;38:912-8. View abstract.
  • Altunbasak S, Baytok V, Tasouji M, et al. Asymptomatic hyperammonemia in children treated with valproic acid. J Child Neurol 1997;12:461-3.
  • Anand I, Chandrashekhan Y, De Giuli F, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998;12:291-9. View abstract.
  • Angelova-Fischer I, Rippke F, Fischer TW, Neufang G, Zillikens D. A double-blind, randomized, vehicle-controlled efficacy assessment study of a skin care formulation for improvement of mild to moderately severe acne. J Eur Acad Dermatol Venereol. 2013 Jul;27 Suppl 2:6-11. View abstract.
  • Anon. Carnitor (levocarnitine) package insert. Sigma-Tau Pharmaceuticals Inc, Gaithersburg, MD. December 1999.
  • Bachmann HU, Hoffmann A. Interaction of food supplement L-carnitine with oral anticoagulant acenocoumarol. Swiss Med Wkly 2004;134:385.
  • Barditch-Crovo P, Toole J, Hendrix CW, et al. Anti-human immunodeficiency virus (HIV) activitiy, safety, and pharmacokinetics of adefovir dipivoxyl (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 1997;176:406-13. View abstract.
  • Bartels GL, Remme WJ, den Hartog FR, et al. Additional anti-ischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy. Cardiovasc Drugs Ther 1995;9:749-53. View abstract.
  • Bartels GL, Remme WJ, Holwerda KJ, Kruijssen DA. Anti-ischaemic efficacy of L-propionylcarnitine - a promising novel metabolic approach to ischaemia? Eur Heart J 1996;17:414-20. View abstract.
  • Bartels GL, Remme WJ, Pillay M, et al. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol 1994;74:125-30. View abstract.
  • Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312-34. View abstract.
  • Bella R, Biondi R, Raffaele R, Pennisi G. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 1990;10:355-60. View abstract.
  • Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V. Carnitine and Hemodialysis. Am J Kidney Dis. 2003;41(1):S116-S122.
  • Benvenga S, Ruggeri RM, Russo A, et al. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2001;86:3579-94. View abstract.
  • Berthillier G, Eichenberger D, Carrier HN, et al. Carnitine metabolism in early stages of Duchenne muscular dystrophy. Clin Chim Acta 1982;122:369-75. View abstract.
  • Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001;88:63-7.. View abstract.
  • Boehm G, Stahl B. Oligosaccharides from milk. J Nutr 2007;137(3 Suppl 2):847S-849S. View abstract.
  • Bohles H, Sewell AC, Wenzel D. The effect of carnitine supplementation in valproate-induced hyperammonaemia. Acta Paediatr 1996;85:446-9. View abstract.
  • Bonner CM, DeBrie KL, Hug G, et al. Effects of parenteral L-carnitine supplementation on fat metabolism and nutrition in premature neonates. J Pediatr 1995;126:287-92. View abstract.
  • Brass E. Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clin Ther 1995;17:176-85. View abstract.
  • Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 2002;54:589-98. View abstract.
  • Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988;77:767-73. View abstract.
  • Brevetti G, Diehm C, Lambert D, et al. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999;34:1618-24. View abstract.
  • Brevetti G, Perna S, Sabba C, et al. Effect of propionyl-L-carnitine on quality of life in intermittent claudication. Am J Cardiol 1997;79:777-80. View abstract.
  • Brevetti G, Perna S, Sabba C, et al. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995;26:1411-6. View abstract.
  • Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J 1992;13:251-5. View abstract.
  • Brooks JO 3rd, Yesavage JA, Carta A, Bravi D. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychoger 1998;10:193-203. View abstract.
  • Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res 1991;17:225-35. View abstract.
  • Campos Y, Arenas J. Muscle carnitine deficiency associated with zidovudine-induced mitochondrial myopathy. Ann Neurol 1994;36:680-1. View abstract.
  • Capaldo B, Napoli R, Di Bonito P, et al. Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 1991;14:191-5. View abstract.
  • Caponnetto S, Canale C, Masperone MA, et al. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction. Eur Heart J 1994;15:1267-73. View abstract.
  • Castro-Gago M, Eiris-Punal J, Novo-Rodriguez MI, et al. Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital. J Child Neurol 1998;13:546-9. View abstract.
  • Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002;89:895-900. View abstract.
  • Cavallini G, Caracciolo S, Vitali G, et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004;63:641-6. View abstract.
  • Chen Y, Abbate M, Tang L, Cai G, Gong Z, Wei R, Zhou J, Chen X. L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis. Am J Clin Nutr. 2014 Feb;99(2):408-22. View abstract.
  • Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo-controlled, crossover study. Int J Clin Pharmacol Ther Toxicol 1985;23:569-72. View abstract.
  • Cherchi A, Lai C, Onnis E, et al. Propionyl carnitine in stable effort angina. Cardiovasc Drugs Ther 1990;4:481-6. View abstract.
  • Ciacci C, Peluso G, Iannoni E, et al. L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study. Dig Liver Dis 2007;39:922-8. View abstract.
  • Cifone MG, Alesse E, Di Marzio L, et al. Effect of L-carnitine treatment in vivo on apoptosis and ceramide generation in peripheral blood lymphocytes from AIDS patients. Proc Assoc Am Physicians 1997;109:146-53. View abstract.
  • Colombani P, Wenk C, Kunz I, et al. Effects of L-carnitine supplementation on physical performance and energy metabolism of endurance-trained athletes: a double-blind crossover field study. Eur J Appl Physiol Occup Physiol 1996;73:434-9. View abstract.
  • Coulter DL. Carnitine, valproate, and toxicity. J Child Neurol 1991;6:7-14. View abstract.
  • Coulter DL. Prevention of hepatotoxicity recurrence with valproate monotherapy and carnitine. Ann Neurol 1988;24:301.
  • Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage 2006;32:551-9. View abstract.
  • Cruciani RA, Zhang JJ, Manola J, Cella D, Ansari B, Fisch MJ. L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2012 Nov 1;30(31):3864-9. View abstract.
  • Dal Lago A, De Martini D, Flore R, et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs Exp Clin Res 1999;25:29-36. View abstract.
  • Dalakas MC, Leon-Monzon ME, Bernardini I, et al. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol 1994;35:482-7. View abstract.
  • Davini P, Bigalli A, Lamanna F, Boem A. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res 1992;18:355-65. View abstract.
  • De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D 2002;3:223-31. View abstract.
  • De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: Current perspectives. Epilepsia 1998;39:1216-25. View abstract.
  • Deeks SG, Collier A, Lalezari J, et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997;176:1517-23. View abstract.
  • Ellaway CM, Williams K, Leonard H, et al. Rett syndrome: randomized controlled trial of L-carnitine. J Child Neurol 1999;14:162-7. View abstract.
  • Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003;42:941-67. View abstract.
  • Famularo G, De Simone C, Cifone G. Carnitine stands on its own in HIV infection treatment. Arch Intern Med 1999;159:1143-4. View abstract.
  • FDA. List of All Orphan Products Designations and Approvals. Levocarnitine. Available at: http://www.fda.gov/orphan/designat/alldes.rtf
  • Freeman JM, Vining EPG, Cost S, Singhi P. Does carnitine administration improve the symptoms attributed to anticonvulsant medications? A double-blinded, crossover study. Pediatrics 1994;93:893-5. View abstract.
  • Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16:101-6. View abstract.
  • Gentile V, Vicini P, Prigiotti G, et al. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 2004;20:1377-84. View abstract.
  • Georgala S, Schulpis KH, Georgala C, Michas T. L-carnitine supplementation in patients with cystic acne on isotretinoin therapy. J Eur Acad Dermatol Venereol 1999;13:205-9. View abstract.
  • Georges B, Galland S, Rigault C, et al. Beneficial effects of L-carnitine in myoblastic C2C12 cells. Interaction with zidovudine. Biochem Pharmacol 2003;65:1483-8.. View abstract.
  • Ghidini O, Azzurro M, Vita G, Sartori G. Evaluation of the therapeutic efficacy of L-carnitine in congestive heart failure. Int J Clin Pharmacol Ther Toxicol 1988;26:217-20. View abstract.
  • Goa KL, Brogden RN. l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs. 1987 Jul;34(1):1-24. View abstract.
  • Goral S. Levocarnitine and muscle metabolism in patients with end-stage renal disease. J Ren Nutr 1998;8:118-21. View abstract.
  • Graziano F, Bisonni R, Catalano V, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer 2002;86:1854-7. View abstract.
  • Hart AM, Wilson AD, Montovani C, et al. Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004;18:1549-60. View abstract.
  • Hatamkhani S, Khalili H, Karimzadeh I, Dashti-Khavidaki S, Abdollahi A, Jafari S. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. J Gastroenterol. Hepatol. 2014 May;29(5):997-1004. View abstract.
  • Heinonen OJ. Carnitine and physical exercise. Sports Med 1996;22:109-32. Sports Med 1996;22:109-32. View abstract.
  • Heuberger W, Berardi S, Jacky E, et al. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 1998;54:503-8. View abstract.
  • Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001;110:616-22.. View abstract.
  • Hirose S, Mitsudome A, Yasumoto S, et al. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics 1998;101:E9 (abstract). View abstract.
  • Hlais S, , Reslan DR, , Sarieddine HK, , Nasreddine L, , Taan G, , Azar S, , Obeid OA. Effect of lysine, , vitamin B(6), , and carnitine supplementation on the lipid profile of male patients with hypertriglyceridemia: a 12-week, , open-label, , randomized, , placebo-controlled trial. Clin Ther. 2012 Aug;34(8):1674-82. View abstract.
  • Hollyer T, Boon H, Georgousis A, et al. The use of CAM by women suffering from nausea and vomiting during pregnancy. BMC Comp Altern Med 2002;2:5. View abstract.
  • Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 1989;2:469-73. View abstract.
  • Huang H, Song L, Zhang H, Zhang H, Zhang J, Zhao W. Influence of L-carnitine supplementation on serum lipid profile in hemodialysis patients: a systematic review and meta-analysis. Kidney Blood Press Res. 2013;38(1):31-41. View abstract.
  • Hug G, McGraw CA, Bates SR, et al. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J Pediatr 1991;119:799-802. View abstract.
  • Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002;13:708-14.. View abstract.
  • Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995;26:380-7. View abstract.
  • Ishikura H, Matsuo N, Matsubara M, et al. Valproic acid overdose and L-carnitine therapy. J Anal Toxicol 1996;20:55-8. View abstract.
  • Jeulin C, Lewin LM. Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa. Hum Reprod Update 1996;2:87-102. View abstract.
  • Jeulin C, Soufir JC, Marson J, et al. [Acetylcarnitine and spermatozoa: relationship with epididymal maturation and motility in the boar and man]. Reprod Nutr Develop 1988;28:1317-27. View abstract.
  • Jones MG, Goodwin CS, Amjad S, Chalmers RA. Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndrome. Clin Chim Acta 2005;360:173-7. View abstract.
  • Jun DW, Kim BI, Cho YK, Kim HJ, Kwon YO, Park SY, Han SY, Baek YH, Jung YJ, Kim HY, Kim W, Heo J, Woo HY, Hwang SG, Rim KS, Choi JY, Bae SH, Lee YS, Lim YS,Cheong JY, Cho SW, Lee BS, Kim SH, Sohn JH, Kim TY, Paik YH, Kim JK, Lee KS. Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. Clin Mol Hepatol. 2013 Jun;19(2):165-72. View abstract.
  • Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy. J Am Med Assoc 1999;282:2305-12. View abstract.
  • Karl M, Rubenstein M, Rudnick C, Brejda J. A multicenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability). J Clin Lipidology 2012;6:150-158. View abstract.
  • Kletzmayr J, Mayer G, Legenstein E, et al. Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int 1999;69:93-106. View abstract.
  • Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013 May;19(5):576-85. View abstract.
  • Krahenbuhl S, Reichen J. Carnitine metabolism in patients with chronic liver disease. Hepatology 1997;25:148-53. View abstract.
  • Krahenbuhl S. Carnitine metabolism in chronic liver disease. Life Sci 1996;59:1579-99. View abstract.
  • Kurul S, Dirik E, Iscan A. Serum carnitine levels during oxcarbazepine and carbamazepine monotherapies in children with epilepsy. J Child Neurol 2003;18:552-4. View abstract.
  • Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Han KH, Yuen MF. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut. 2014 Jun;63(6):996-1004. View abstract.
  • Laker MF, Green C, Bhuiyan AK, Shuster S. Isotretinoin and serum lipids: studies on fatty acid, apolipoprotein and intermediary metabolism. Br J Dermatol 1987;117:203-6. View abstract.
  • Lebrun C, Alchaar H, Candito M, et al. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler 2006;12:321-4. View abstract.
  • Lenzi A, Sgro P, Salacone P, et al. A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia. Fertil Steril 2004;81:1578-84. View abstract.
  • Liu J, Head E, Kuratsune H, et al. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann N Y Acad Sci 2004;1033:117-31. View abstract.
  • Liu Q, Garner P, Wang Y, Huang B, Smith H. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health. 2008;8:365. View abstract.
  • Löster H, Miehe K, Punzel M, et al. Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. Cardiovasc.Drugs Ther 1999;13:537-46. View abstract.
  • Madsen KL, Preisler N, Orngreen MC, Andersen SP, Olesen JH, Lund AM, Vissing J. Patients with medium-chain acyl-coenzyme a dehydrogenase deficiency have impaired oxidation of fat during exercise but no effect of L-carnitine supplementation. J Clin Endocrinol Metab. 2013 Apr;98(4):1667-75. View abstract.
  • Malaguarnera M, Cammalleri L, Gargante MP, et al. L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr 2007;86:1738-44. View abstract.
  • Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992;42:1101-4. View abstract.
  • Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 322 patients with cancer cachexia. Oncologist 2010;15:200-11. View abstract.
  • Marconi C, Sassi G, Carpinelli A, Cerretelli P. Effects of L-carnitine loading on the aerobic and anaerobic performance of endurance athletes. Eur J Appl Physiol Occup Physiol 1985;54:131-5. View abstract.
  • Marthaler NP, Visarius T, Kupfer A, Lauterburg BH. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol 1999;44:170-2. View abstract.
  • Martinez E, Domingo P, Roca-Cusachs A. Potentiation of acenocoumarol action by L-carnitine. J Intern Med 1993;233:94.
  • Melegh B, Kerner J, Sandor A, et al. Oral L-carnitine supplementation in low-birth-weight newborns: a study on neonates requiring combined parenteral and enteral nutrition. Acta Paediatr Hung 1986;27:253-8. View abstract.
  • Memeo A., Loiero M. Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. Clin Drug Investig 2008;28(8):495-500. View abstract.
  • Mezzina C, De Grandis D, Calvani M, et al. Idiopathic facial paralysis: new therapeutic prospects with acetyl-L-carnitine. Int J Clin Pharmacol Res 1992;12:299-304. View abstract.
  • Mingrone G, Greco AV, Capristo E, et al. L-carnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr 1999;18:77-82. View abstract.
  • Mingrone G. Carnitine in type 2 diabetes. Ann N Y Acad Sci 2004;1033:99-107. View abstract.
  • Mintz M. Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. J Child Neurol 1995;10:S40-4. View abstract.
  • Miyagawa T, Kawamura H, Obuchi M, Ikesaki A, Ozaki A, Tokunaga K, Inoue Y, Honda M. Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PLoS One. 2013;8(1):e53707. View abstract.
  • Moncada ML, Vicari E, Cimino C, et al. Effect of acetylcarnitine treatment in oligoasthenospermic patients. Acta Europ Fertil 1992;23:221-4. View abstract.
  • Moretti S, Alesse E, Di Marzio L, et al. Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: a pilot study. Blood 1998;91:3817-24. View abstract.
  • Murakami K, Sugimoto T, Woo M, et al. Effect of L-carnitine supplementation on acute valproate intoxication. Epilepsia 1996;37:687-9. View abstract.
  • Nebbioso M, Evangelista M, Librando A, Plateroti AM, Pescosolido N. Iatrogenic dry eye disease: an eledoisin/carnitine and osmolyte drops study. Biomed Pharmacother. 2013 Sep;67(7):659-63. View abstract.
  • Neri S, Pistone G, Saraceno B, et al. L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. Neuropsychobiology 2003;47:94-7. View abstract.
  • Noble S, Goa KL. Adefovir dipivoxil. Drugs 1999;58:479-87. View abstract.
  • Novak M. Carnitine supplementation in soy-based formula-fed infants. Biol Neonate 1990;58:89-92. View abstract.
  • Nuesch R, Rossetto M, Martina B. Plasma and urine carnitine concentrations in well-trained athletes at rest and after exercise. Influence of L-carnitine intake. Drugs Exp Clin Res 1999;25:167-71. View abstract.
  • Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982;101:782-5. View abstract.
  • Onofrj M, Fulgente T, Melchionda D, et al. L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. Int J Clin Pharmacol Res 1995;15:9-15. View abstract.
  • Opala G, Winter S, Vance C, et al. The effect of valproic acid on plasma carnitine levels. Am J Dis Child 1991;145:999-1001. View abstract.
  • Passeri M, Cucinotta D, Bonati PA, et al. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. Int J Clin Pharmacol Res 1990;10:75-9. View abstract.
  • Persico G, Amato B, Aprea G, et al. The early effects of intravenous L-propionyl carnitine on ulcerative trophic lesions of the lower limbs in arteriopathic patients: a controlled randomized study. Drugs Exp Clin Res 1995;21:187-98. View abstract.
  • Pettegrew JW, Klunk WE, Panchalingam K, et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 1995;16:1-4. View abstract.
  • Pistone G, Marino A, Leotta C, et al. Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue. Drugs Aging 2003;20:761-7. View abstract.
  • Plioplys AV, Kasnicka I. L-carnitine as a treatment for Rett syndrome. South Med J 1993;86:1411-2. View abstract.
  • Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Neuropsychobiology 1997;35:16-23. View abstract.
  • Pons-Rejraji H, Brugnon F, Sion B, Maqdasy S, Gouby G, Pereira B, Marceau G, Gremeau AS, Drevet J, Grizard G, Janny L, Tauveron I. Evaluation of torvastatin efficacy and toxicity on spermatozoa, accessory glands and gonadal hormones of healthy men: a pilot prospective clinical trial. Reprod Biol Endocrinol. 2014 Jul 12;12:65. View abstract.
  • Postiglione A, Soricelli A, Cicerano U, et al. Effect of acute administration of L-acetyl carnitine on cerebral blood flow in patients with chronic cerebral infarct. Pharmacol Res 1991;23:241-6. View abstract.
  • Pourmand G, Movahedin M, Dehghani S, Mehrsai A, Ahmadi A, Pourhosein M, Hoseini M, Ziloochi M, Heidari F, Beladi L, Noori M. Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology. 2014 Oct;84(4):821-5. View abstract.
  • Prohaska ES, Muzyk AJ, Rivelli SK. Levocarnitine-induced hypophosphatemia in a hemodialysis patient with acute valproic acid toxicity. J Neuropsychiatry Clin Neurosci. 2012 Winter;24(1):E18-9. View abstract.
  • Rai G, Wright G, Scott L, et al. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 1990;11:638-47. View abstract.
  • Ramos AC, Barrucand L, Elias PR, et al. Carnitine supplementation in diphtheria. Indian Pediatr 1992;29:1501-5. View abstract.
  • Ramos AC, Elias PR, Barrucand L, Da Silva JA. The protective effect of carnitine in human diphtheric myocarditis. Pediatr Res 1984;18:815-9. View abstract.
  • Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000;34:630-8. View abstract.
  • Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci 2004;1033:30-41. View abstract.
  • Riva R, Albani F, Gobbi G, et al. Carnitine disposition before and during valproate therapy in patients with epilepsy. Epilepsia 1993;34:184-7. View abstract.
  • Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 2000;139:S120-3. View abstract.
  • Rondanelli M, Opizzi A, Perna S, Faliva M, Solerte SB, Fioravanti M, Klersy C, Edda C, Maddalena P, Luciano S, Paola C, Emanuela C, Claudia S, Donini LM. Acute effect on satiety, resting energy expenditure, respiratory quotient, glucagon-like peptide-1, free fatty acids, and glycerol following consumption of a combination of bioactive food ingredients in overweight subjects. J Am Coll Nutr. 2013;32(1):41-9. View abstract.
  • Salvioli G, Neri M. L-acetylcarnitine treatment of mental decline in the elderly. Drugs Exp Clin Res 1994;20:169-76. View abstract.
  • Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's Disease. Arch Neurol 1992;49:1137-41. View abstract.
  • Scaglia F, Longo N. Primary and secondary alterations of neonatal carnitine metabolism. Semin Perinatol 1999;23:152-61. View abstract.
  • Scarpini E, Sacilotto G, Baron P, et al. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J Peripher Nerv Syst 1997;2:250-2. View abstract.
  • Schlenzig JS, Charpentier C, Rabier D, et al. L-carnitine: a way to decrease cellular toxicity of ifosfamide? Eur J Pediatr 1995;154:686-7. View abstract.
  • Schmidt-Sommerfeld E, Penn D, Wolf H. Carnitine deficiency in premature infants receiving total parenteral nutrition: effect of L-carnitine supplementation. J Pediatr 1983;102:931-5. View abstract.
  • Schmidt-Sommerfeld E, Penn D. Carnitine and total parenteral nutrition of the neonate. Biol Neonate 1990;58:81-8. View abstract.
  • Schoderbeck M, Auer B, Legenstein E, et al. Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytes. J Perinat Med 1995;23:477-85. View abstract.
  • Sekas G, Paul HS. Hyperammonemia and carnitine deficiency in a patient receiving sulfadiazine and pyrimethamine. Am J Med 1993;95:112-3. View abstract.
  • Serati AR, Motamedi MR, Emami S, et al. L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. Cardiology 2010;116:178-82. View abstract.
  • Shang R, Sun Z, Li H. Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2014 Jul 21;14:88. View abstract.
  • Shapira Y, Gutman A. Muscle carnitine deficiency in patients using valproic acid. J Pediatrics 1991;118:646-9. View abstract.
  • Sima AAF, Calvani M, Mehra M, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: An analysis of two randomized, placebo-controlled trials. Diabetes Care 2005;28:89-94. View abstract.
  • Singh RB, Niaz MA, Agarwal P, et al. A randomized, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996;72:45-50. View abstract.
  • Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care 2000;3:417-24. View abstract.
  • Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's Disease. Neurology 1991;41:1726-32. View abstract.
  • Stanley CA. Carnitine deficiency disorders in children. Ann N Y Acad Sci 2004;1033:42-51. View abstract.
  • Tabei SM, Mazloom M, Shahriari M, Zareifar S, Azimi A, Hadaegh A, Karimi M. Determining and surveying the role of carnitine and folic acid to decrease fatigue in ß-thalassemia minor subjects. Pediatr Hematol Oncol. 2013 Nov;30(8):742-7. View abstract.
  • Tamamogullari N, Silig Y, Icagasioglu S, Atalay A. Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications 1999;13:251-3. View abstract.
  • Tanphaichitr N. In vitro stimulation of human sperm motility by acetylcarnitine. Int J Fertil 1977;22:85-91. View abstract.
  • Tempesta E, Casella L, Pirrongelli C, et al. L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 1987;13:417-23. View abstract.
  • Tempesta E, Troncon R, Janiri L, et al. Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism. Int J Clin Pharmacol Res 1990;10:101-7. View abstract.
  • Thal LJ, Calvani M, Amato A, et al. A 1-year controlled trial of acetyl-l-carnitine in early onset AD. Neurol 2000;55:805-10. View abstract.
  • Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's Disease. Neurology 1996;47:705-11. View abstract.
  • Thom H, Carter PE, Cole GF, et al. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev Med Child Neurol 1991;33:795-802. View abstract.
  • Tsoko M, Beauseigneur F, Gresti J, et al. Enhancement of activities relative to fatty acid oxidation in the liver of rats depleted of L-carnitine by D-carnitine and a gamma- butyrobetaine hydroxylase inhibitor. Biochem Pharmacol 1995;49:1403-10. View abstract.
  • Van Wouwe JP. Carnitine deficiency during valproic acid treatment. Int J Vitam Nutr Res 1995;65:211-4. View abstract.
  • Vance CK, Vance H, Winter SC, et al. Control of valproate-induced hepatotoxicity with carnitine. Ann Neurol 1989;26:456.
  • Vecchiet L, Di Lisa F, Pieralisi G, et al. Influence of L-carnitine administration on maximal physical exercise. Eur J Appl Physiol Occup Physiol 1990;61:486-90. View abstract.
  • Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med 2004;66:276-82. View abstract.
  • Vicari E, La Vignera S, Calogero AE. Antioxidant treatment with carnitines is effective in infertile patients with prostatovesiculoepididymitis and elevated seminal leukocyte concentrations after treatment with nonsteroidal anti-inflammatory compounds. Fertil Steril 2002;78:1203-8.. View abstract.
  • Vidal-Casariego A, Burgos-Peláez R, Martínez-Faedo C, Calvo-Gracia F, Valero-Zanuy MÁ, Luengo-Pérez LM, Cuerda-Compés C. Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):234-8. View abstract.
  • Winter SC, Szabo-Aczel S, Curry CJR, et al. Plasma carnitine deficiency: Clinical observations in 51 pediatric patients. Am J Dis Child 1987;141:660-5. View abstract.
  • Wu X, Huang W, Prasad PD, et al. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 1999;290:1482-92. View abstract.
  • Xu XQ, Jing ZC, Jiang X, et al. [Clinical efficacy of intravenous L-carnitine in patients with right-sided heart failure induced by pulmonary arterial hypertension]. Zhonghua Xin.Xue.Guan.Bing.Za Zhi. 2010;38:152-5. View abstract.
  • Yang SK, Xiao L, Song PA, Xu X, Liu FY, Sun L. Effect of L-carnitine therapy on patients in maintenance hemodialysis: a systematic review and meta-analysis. J Nephrol. 2014 Jun;27(3):317-29. View abstract.
  • Zelnik N, Fridkis I, Gruener N. Reduced carnitine and antiepileptic drugs: cause relationship or co-existence? Acta Paediatr 1995;84:93-5. View abstract.
  • Zhang JJ, Wu ZB, Cai YJ, Ke B, Huang YJ, Qiu CP, Yang YB, Shi LY, Qin J. L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: a randomized controlled study. Nutr J. 2014 Nov 26;13:110. View abstract.

More Resources for L-CARNITINE

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version. © Therapeutic Research Faculty 2009.